https://biolegacyresearch.com/phrma-files-for-summary-judgment-in-ira-drug-pricing-suit/ 2023-08-14T19:02:29+00:00 https://biolegacyresearch.com/oncopeptides-fights-latest-fda-attempt-to-revoke-pepaxto-approval/ 2023-08-14T20:44:36+00:00 https://biolegacyresearch.com/sec-will-probe-illumina-with-investigation-into-grail-acquisition/ 2023-08-14T20:46:29+00:00 https://biolegacyresearch.com/off-the-shelf-software-for-use-in-medical-devices-guidance-replaces-1999-version/ 2023-08-15T17:56:23+00:00 https://biolegacyresearch.com/yet-another-class-i-recall-for-certain-philips-respironics-trilogy-ventilators/ 2023-08-15T18:59:26+00:00 https://biolegacyresearch.com/quick-notes-european-edition/ 2023-08-15T19:45:00+00:00 https://biolegacyresearch.com/hhs-lambasts-chamber-for-fighting-iras-pricing-program-seeks-dismissal-of-suit/ 2023-08-15T20:15:23+00:00 https://biolegacyresearch.com/amgen-horizon-ask-court-to-uphold-their-constitutional-defenses-in-ftcs-antitrust-case/ 2023-08-15T20:25:55+00:00 https://biolegacyresearch.com/meeting-planner-week-of-aug-14-2023/ 2023-08-16T17:54:00+00:00 https://biolegacyresearch.com/biocon-malaysia-plant-gets-483-for-sterility-testing-quality-control-issues/ 2023-08-16T18:30:13+00:00 https://biolegacyresearch.com/cdrh-provides-tips-for-submitting-comments-on-guidances/ 2023-08-16T19:00:26+00:00 https://biolegacyresearch.com/warning-letter-roundup-astrazeneca-hit-for-misleading-breztri-ads-other-drugmakers-slapped-for-selling-unapproved-drugs-gmp-violations/ 2023-08-16T20:35:33+00:00 https://biolegacyresearch.com/quick-notes-devices-entering-the-market-bring-new-ways-to-provide-care/ 2023-08-16T21:18:11+00:00 https://biolegacyresearch.com/another-class-i-recall-for-medtronic-hemodialysis-catheters/ 2023-08-17T17:38:09+00:00 https://biolegacyresearch.com/analyze-data-from-internal-audits-to-gain-operational-benefits/ 2023-08-17T18:00:49+00:00 https://biolegacyresearch.com/appeals-court-lifts-ban-on-abortion-pill-but-holds-back-on-mail-order/ 2023-08-17T19:11:20+00:00 https://biolegacyresearch.com/fda-finalizes-guidance-on-informed-consent-process/ 2023-08-17T19:30:07+00:00 https://biolegacyresearch.com/fda-noncompliance-letter-hits-washington-biotech-for-not-submitting-trial-results/ 2023-08-17T20:36:50+00:00 https://biolegacyresearch.com/regulatory-update-week-of-aug-14-2023/ 2023-08-18T18:14:24+00:00 https://biolegacyresearch.com/florida-continues-battle-over-fda-foia-requests-for-canadian-drug-import-plan/ 2023-08-18T19:05:54+00:00 https://biolegacyresearch.com/ipsen-clears-hurdles-to-get-fda-approval-for-first-drug-for-ultra-rare-bone-disease/ 2023-08-18T19:31:03+00:00 https://biolegacyresearch.com/abiomed-recalls-labeling-for-its-impella-rp-smart-assist-catheter/ 2023-08-18T19:40:35+00:00 https://biolegacyresearch.com/key-aspects-of-oklahoma-pbm-law-rejected-by-federal-appeals-court/ 2023-08-18T20:20:18+00:00 https://biolegacyresearch.com/legislative-update-week-of-aug-21-2023/ 2023-08-21T17:55:20+00:00 https://biolegacyresearch.com/circulatory-system-devices-panel-will-review-two-hypertension-treatment-devices/ 2023-08-21T18:25:20+00:00 https://biolegacyresearch.com/krystal-biotech-sells-pva-for-100m-to-undisclosed-buyer/ 2023-08-21T18:34:55+00:00 https://biolegacyresearch.com/regeneron-bounces-back-with-approval-of-two-drugs-from-catalent-plant/ 2023-08-21T19:00:21+00:00 https://biolegacyresearch.com/fda-issues-product-specific-guidelines-for-generic-drug-development/ 2023-08-21T19:18:33+00:00 https://biolegacyresearch.com/ais-shot-in-the-arm-of-science-and-the-concerns-we-need-to-address/ 2023-08-22T18:23:05+00:00 https://biolegacyresearch.com/teva-gets-225m-doj-penalty-glenmark-30m-for-price-fixing-critical-generic-drugs/ 2023-08-22T18:50:00+00:00 https://biolegacyresearch.com/philips-issues-urgent-notice-to-avoid-unintended-radiation-from-stuck-foot-switch/ 2023-08-22T19:10:43+00:00 https://biolegacyresearch.com/aarp-files-amicus-brief-supporting-ira-boehringer-ingelheim-joins-challenge-against/ 2023-08-22T20:40:07+00:00 https://biolegacyresearch.com/califf-fda-will-spend-hoped-for-funding-increase-on-shoring-up-internal-data-quality/ 2023-08-22T22:58:47+00:00 https://biolegacyresearch.com/panel-supports-hypertension-device-despite-concerns-about-effect-durability/ 2023-08-23T17:25:57+00:00 https://biolegacyresearch.com/meeting-planner-week-of-aug-21-2023/ 2023-08-23T19:15:15+00:00 https://biolegacyresearch.com/intarcias-implantable-diabetes-drug-device-combo-gets-public-hearing/ 2023-08-23T19:45:08+00:00 https://biolegacyresearch.com/no-monopoly-will-result-from-merger-amgen-and-horizon-say-in-legal-brief/ 2023-08-23T20:15:12+00:00 https://biolegacyresearch.com/apellis-eye-drug-safety-probe-reveals-issues-with-injection-kits/ 2023-08-23T20:45:00+00:00 https://biolegacyresearch.com/fda-panel-agrees-medtronic-renal-denervation-device-is-safe-but-not-very-effective/ 2023-08-24T17:00:18+00:00 https://biolegacyresearch.com/research-round-up-august-2023/ 2023-08-24T17:30:37+00:00 https://biolegacyresearch.com/draeger-carina-ventilator-recalled-for-potential-pe-pur-airpath-contaminants/ 2023-08-24T18:00:15+00:00 https://biolegacyresearch.com/hhs-awards-1-4b-for-new-covid-tools-24m-for-mrna-cancer-fighting-tech/ 2023-08-24T18:45:28+00:00 https://biolegacyresearch.com/quick-notes-medical-device-development-and-approvals/ 2023-08-25T16:52:11+00:00 https://biolegacyresearch.com/regulatory-update-week-of-aug-21-2023/ 2023-08-25T17:30:23+00:00 https://biolegacyresearch.com/fda-to-delay-enforcement-of-dscsa-requirements-until-november-2024/ 2023-08-25T18:00:25+00:00 https://biolegacyresearch.com/cvs-takes-aim-at-private-label-biosimilars-with-new-subsidiary-cordavis/ 2023-08-25T19:24:49+00:00 https://biolegacyresearch.com/medicare-negotiation-drugs-may-be-revealed-early-astrazeneca-joins-ira-challenge/ 2023-08-25T19:55:11+00:00 https://biolegacyresearch.com/withings-400-health-station-gets-fda-clearance-to-measure-ecg-body-composition/ 2023-08-28T16:42:55+00:00 https://biolegacyresearch.com/legislative-update-week-of-aug-28-2023/ 2023-08-28T16:52:07+00:00 https://biolegacyresearch.com/fda-seeks-public-comment-on-withdrawal-of-pepaxto-accelerated-approval/ 2023-08-28T19:37:26+00:00 https://biolegacyresearch.com/rethink-criteria-for-monitoring-psychedelics-trials-commenters-tell-fda/ 2023-08-28T20:13:26+00:00 https://biolegacyresearch.com/ftc-pauses-its-efforts-to-block-amgen-27-8b-purchase-of-horizon-therapeutics/ 2023-08-28T20:21:17+00:00 https://biolegacyresearch.com/pfizer-reopens-rocky-mount-n-c-plant-after-tornado-destruction/ 2023-08-29T17:34:05+00:00 https://biolegacyresearch.com/fda-inspection-shows-fisher-wallace-failed-to-report-serious-adverse-events/ 2023-08-29T18:20:49+00:00 https://biolegacyresearch.com/ethylene-oxide-consent-decree-means-epa-must-complete-work-by-march-2024/ 2023-08-29T19:10:24+00:00 https://biolegacyresearch.com/ftc-and-doj-host-workshop-on-new-merger-guidelines/ 2023-08-29T19:30:37+00:00 https://biolegacyresearch.com/drugmakers-voice-strong-opposition-to-medicare-drug-price-negotiation-list/ 2023-08-29T20:15:55+00:00 https://biolegacyresearch.com/meeting-planner-week-of-aug-28-2023/ 2023-08-30T20:07:44+00:00 https://biolegacyresearch.com/three-fda-guidances-using-real-world-data-in-observational-studies-and-dscsa/ 2023-08-30T20:55:00+00:00 https://biolegacyresearch.com/quick-notes-for-aug-30-2023/ 2023-08-30T21:10:54+00:00 https://biolegacyresearch.com/novo-nordisk-buys-another-obesity-drugmaker-as-wegovy-fever-continues-to-rise/ 2023-08-30T21:15:59+00:00 https://biolegacyresearch.com/companies-regulated-by-cdrh-near-top-of-fda-ombudsmans-frequent-flyer-list/ 2023-08-30T21:20:00+00:00 https://biolegacyresearch.com/outlooks-lytenava-gets-crl-for-manufacturing-issues-more-evidence/ 2023-08-31T18:53:19+00:00 https://biolegacyresearch.com/hamilton-medical-sees-class-i-recall-for-ventilators-that-stop-without-notice/ 2023-08-31T19:10:24+00:00 https://biolegacyresearch.com/jama-analysis-shows-expedited-programs-shave-up-to-2-years-off-development-review/ 2023-08-31T19:40:43+00:00 https://biolegacyresearch.com/sen-warren-rep-jayapal-ask-fda-to-close-loopholes-that-keep-generics-off-the-market/ 2023-08-31T20:10:36+00:00 https://biolegacyresearch.com/advamed-mdma-support-but-express-concerns-over-cms-coverage-of-breakthrough-devices/ 2023-08-31T20:30:35+00:00 https://biolegacyresearch.com/getinge-sees-yet-another-class-i-recall-for-intra-aortic-balloon-pump/ 2023-09-01T17:17:30+00:00 https://biolegacyresearch.com/regulatory-update-week-of-sept-4-2023/ 2023-09-01T17:24:57+00:00 https://biolegacyresearch.com/cder-quality-management-maturity-meant-to-support-quality-culture-mindset/ 2023-09-01T17:50:31+00:00 https://biolegacyresearch.com/27-8-billion-amgen-and-horizon-merger-gets-ftc-go-ahead-with-consent-order/ 2023-09-01T18:51:15+00:00 https://biolegacyresearch.com/fda-issues-guidances-on-post-warning-letter-meetings-verification-of-returned-drugs/ 2023-09-01T19:12:43+00:00 https://biolegacyresearch.com/patient-engagement-adcomm-will-tackle-cdrh-goals-for-outpatient-device-access/ 2023-09-05T17:06:22+00:00 https://biolegacyresearch.com/guidances-released-on-epcis-standard-for-dscsa-compliance-pulmonary-disease-drug-development/ 2023-09-05T19:23:30+00:00 https://biolegacyresearch.com/major-industry-groups-offer-feedback-on-ichs-e6r3-guidelines/ 2023-09-05T20:18:48+00:00 https://biolegacyresearch.com/novartis-joins-fight-against-ira-with-lawsuit-challenging-constitutionality/ 2023-09-05T20:45:00+00:00 https://biolegacyresearch.com/meeting-planner-sept-4-2023/ 2023-09-06T17:46:02+00:00 https://biolegacyresearch.com/medtronic-sued-for-disclosing-hipaa-protected-pii-and-phi-to-google-and-others/ 2023-09-06T19:10:57+00:00 https://biolegacyresearch.com/fda-aims-to-modernize-510k-device-program-in-trio-of-draft-guidances/ 2023-09-06T19:30:28+00:00 https://biolegacyresearch.com/ftc-doj-merger-guidance-still-lacking-say-panel-members-at-workshop/ 2023-09-06T20:25:05+00:00 https://biolegacyresearch.com/lightstrike-uv-broad-spectrum-robot-gets-fda-de-novo-clearance-for-disinfection/ 2023-09-06T20:45:59+00:00 https://biolegacyresearch.com/eu-gmp-report-september-2023/ 2023-09-07T17:00:27+00:00 https://biolegacyresearch.com/peac-committee-offers-device-design-advice-to-cdrh/ 2023-09-07T18:00:36+00:00 https://biolegacyresearch.com/fda-record-review-results-in-warning-letter-for-otc-drugmaker/ 2023-09-07T18:30:48+00:00 https://biolegacyresearch.com/revised-guidance-advises-on-use-of-iso-10993-1-for-device-biocompatibility/ 2023-09-07T19:00:27+00:00 https://biolegacyresearch.com/impact-of-ira-on-rd-could-result-in-fewer-small-molecule-drugs-study-says/ 2023-09-07T20:10:25+00:00 https://biolegacyresearch.com/uk-rejoins-eu-research-collaboration-and-funding-source/ 2023-09-08T18:25:22+00:00 https://biolegacyresearch.com/human-factor-studies-for-combination-products-tackled-in-fda-final-guidance/ 2023-09-08T19:19:07+00:00 https://biolegacyresearch.com/quick-notes-for-sept-8-2023/ 2023-09-08T20:00:07+00:00 https://biolegacyresearch.com/philips-close-to-616m-settlement-related-to-recall-of-sleep-and-respiratory-devices/ 2023-09-08T20:05:44+00:00 https://biolegacyresearch.com/legislative-update-sept-11-2023/ 2023-09-11T16:30:21+00:00 https://biolegacyresearch.com/risk-assessment-requires-more-than-fmea-expert-says/ 2023-09-11T17:50:00+00:00 https://biolegacyresearch.com/pbm-drug-price-transparency-bill-introduced-by-three-house-committees/ 2023-09-11T18:40:00+00:00 https://biolegacyresearch.com/regulatory-experts-highlight-best-practices-for-fda-inspection-readiness/ 2023-09-11T19:40:00+00:00 https://biolegacyresearch.com/doj-and-danco-ask-supreme-court-to-overturn-mifeprex-ruling/ 2023-09-11T20:24:35+00:00 https://biolegacyresearch.com/quick-notes-for-sept-12-2023/ 2023-09-12T19:07:09+00:00 https://biolegacyresearch.com/fda-seeks-applicants-for-cdrp-pilot-program/ 2023-09-12T19:53:36+00:00 https://biolegacyresearch.com/fda-ftc-resources-limited-for-medical-device-ad-enforcement-says-gao-report/ 2023-09-12T20:30:54+00:00 https://biolegacyresearch.com/unapproved-eye-drops-earn-drug-makers-eight-warning-letters-two-import-alerts/ 2023-09-12T20:45:46+00:00 https://biolegacyresearch.com/amgen-horizon-merger-up-for-public-comments-before-ftc-will-finalize-it/ 2023-09-12T21:15:25+00:00 https://biolegacyresearch.com/selling-drugs-medical-devices-to-iraq-is-not-an-act-of-terrorism-companies-say/ 2023-09-13T18:00:16+00:00 https://biolegacyresearch.com/drug-repackaging-company-safecor-cited-in-warning-letter-for-mixing-up-drugs/ 2023-09-13T19:00:45+00:00 https://biolegacyresearch.com/jazz-pharma-becomes-25th-drugmaker-to-restrict-participation-in-340b-program/ 2023-09-13T19:15:00+00:00 https://biolegacyresearch.com/hhs-responds-to-mercks-lawsuit-over-ira-drug-pricing-provision/ 2023-09-13T19:30:00+00:00 https://biolegacyresearch.com/quick-notes-for-sept-13-2023/ 2023-09-13T19:45:00+00:00 https://biolegacyresearch.com/cder-opens-docket-for-comment-on-quality-management-maturity-program/ 2023-09-14T19:35:15+00:00 https://biolegacyresearch.com/fda-drug-approvals-august-2023/ 2023-09-14T19:50:14+00:00 https://biolegacyresearch.com/generic-drug-shortages-getting-worse-say-congressional-witnesses/ 2023-09-14T20:05:12+00:00 https://biolegacyresearch.com/fda-guidance-quick-notes-for-sept-14-2023/ 2023-09-14T20:20:24+00:00 https://biolegacyresearch.com/ftc-votes-unanimously-to-issue-policy-warning-drugmakers-against-improper-patents/ 2023-09-14T20:25:45+00:00 https://biolegacyresearch.com/cisplatin-at-nearly-normal-levels-after-fda-taps-manufacturers-to-reduce-cancer-drug-shortages/ 2023-09-15T17:07:14+00:00 https://biolegacyresearch.com/regulatory-update-week-of-sept-18-2023/ 2023-09-15T17:12:00+00:00 https://biolegacyresearch.com/cder-soundly-rejects-oncopeptides-pepaxto-appeal/ 2023-09-15T20:20:39+00:00 https://biolegacyresearch.com/in-wake-of-allegations-gao-issues-report-on-political-interference-across-hhs/ 2023-09-15T20:53:40+00:00 https://biolegacyresearch.com/biosimilar-draft-guidances-tackle-labeling-and-interchangeables/ 2023-09-15T20:54:10+00:00 https://biolegacyresearch.com/legislative-update-week-of-sept-18-2023/ 2023-09-18T18:59:14+00:00 https://biolegacyresearch.com/gsk-nabs-fda-approval-for-first-drug-for-treatment-of-myelofibrosis/ 2023-09-18T19:30:13+00:00 https://biolegacyresearch.com/single-trial-can-support-fda-drug-approval-says-draft-guidance/ 2023-09-18T19:45:07+00:00 https://biolegacyresearch.com/compliance-and-a-culture-of-quality-go-hand-in-hand-says-expert/ 2023-09-18T20:00:31+00:00 https://biolegacyresearch.com/fdas-pac-to-discuss-first-in-human-studies-of-artificial-wombs-this-week/ 2023-09-18T20:15:30+00:00 https://biolegacyresearch.com/prescription-drug-use-related-software-output-reviewed-in-draft-guidance/ 2023-09-19T17:16:03+00:00 https://biolegacyresearch.com/celgene-bms-sued-by-bcbs-of-louisiana-for-patent-fraud-of-blockbuster-drug-pomalyst/ 2023-09-19T18:28:43+00:00 https://biolegacyresearch.com/crisis-response-can-build-resiliency-into-supply-chain-business-plans-says-moderna-expert/ 2023-09-19T18:32:42+00:00 https://biolegacyresearch.com/fda-dep-director-says-ai-ml-data-collection-needs-to-avoid-bias/ 2023-09-19T18:45:12+00:00 https://biolegacyresearch.com/cders-cavazzoni-warns-drug-shortages-becoming-more-complex/ 2023-09-19T18:48:07+00:00 https://biolegacyresearch.com/manufacturing-cost-is-key-issue-facing-gene-therapy-products-marks-says/ 2023-09-20T16:54:56+00:00 https://biolegacyresearch.com/cdrh-plan-aims-for-harmonized-international-device-regulations-policies-practices/ 2023-09-20T17:40:21+00:00 https://biolegacyresearch.com/neffy-nasal-spray-alternate-for-epipen-gets-crl-despite-adcomm-endorsement/ 2023-09-20T18:35:04+00:00 https://biolegacyresearch.com/fda-broadens-pandemic-era-guidance-to-cover-trials-during-phes-disasters/ 2023-09-20T20:09:07+00:00 https://biolegacyresearch.com/fdas-pediatric-advisors-artificial-womb-technology-not-yet-ready-for-human-trials/ 2023-09-20T20:25:09+00:00 https://biolegacyresearch.com/meeting-requests-manufacturer-assessments-for-ndas-and-blas-subject-of-draft-guidances/ 2023-09-21T18:30:31+00:00 https://biolegacyresearch.com/lilly-becomes-second-maker-of-glp-1-inhibitors-to-file-lawsuits-against-copycats/ 2023-09-21T19:05:08+00:00 https://biolegacyresearch.com/medline-industries-recall-of-non-sterile-saline-solution-vials-deemed-class-1-by-fda/ 2023-09-21T19:30:51+00:00 https://biolegacyresearch.com/marketing-of-unapproved-biologics-top-concern-for-cber-says-fda-official/ 2023-09-21T20:09:15+00:00 https://biolegacyresearch.com/fda-cited-novo-nordisk-wegovy-ozempic-facility-for-quality-lapses-last-year/ 2023-09-21T20:25:00+00:00 https://biolegacyresearch.com/fda-sets-novartis-voluntary-recall-of-sandimmune-as-class-1/ 2023-09-22T20:24:01+00:00 https://biolegacyresearch.com/nearly-20-percent-of-fda-employees-could-see-furloughs-in-government-shutdown/ 2023-09-22T20:55:00+00:00 https://biolegacyresearch.com/quick-notes-for-sept-22-2023/ 2023-09-22T21:00:04+00:00 https://biolegacyresearch.com/adcomm-agrees-with-fda-votes-down-intarcias-t2-diabetes-combo-product/ 2023-09-22T21:05:29+00:00 https://biolegacyresearch.com/legislative-update-week-of-sept-25-2023/ 2023-09-25T17:42:07+00:00 https://biolegacyresearch.com/fda-greenlights-blockbuster-diabetes-drug-jardiance-for-chronic-kidney-disease/ 2023-09-25T18:30:22+00:00 https://biolegacyresearch.com/fda-under-no-obligation-to-educate-companies-on-inspection-rights-says-expert/ 2023-09-25T19:03:09+00:00 https://biolegacyresearch.com/hamilton-ventilator-recall-deemed-class-i-for-software-issue-causing-device-to-stop/ 2023-09-25T19:25:00+00:00 https://biolegacyresearch.com/quick-notes-european-edition-sept-25-2023/ 2023-09-25T19:40:00+00:00 https://biolegacyresearch.com/cybersecurity-final-guidance-details-system-considerations-for-premarket-submissions/ 2023-09-26T17:32:43+00:00 https://biolegacyresearch.com/pharm-tech-survey-shows-nearly-all-face-drug-shortages-pfizer-plant-shortages-continue-until-2024/ 2023-09-26T19:25:20+00:00 https://biolegacyresearch.com/biosimilars-spell-the-end-of-humiras-blockbuster-empire-or-do-they/ 2023-09-26T19:40:25+00:00 https://biolegacyresearch.com/coherus-slapped-with-crl-for-neulasta-biosimilar-bla-due-to-third-party-filler/ 2023-09-26T20:00:10+00:00 https://biolegacyresearch.com/icer-peterson-health-technology-institute-devise-assessment-framework-for-dhts/ 2023-09-26T21:13:33+00:00 https://biolegacyresearch.com/european-parliament-and-ema-agree-on-new-application-fee-structure/ 2023-09-27T18:44:18+00:00 https://biolegacyresearch.com/bms-other-drugmakers-sign-drug-price-negotiation-agreements-with-cms/ 2023-09-27T18:54:19+00:00 https://biolegacyresearch.com/pharma-companies-rake-in-185b-on-just-four-drugs-via-patent-thickets-says-report/ 2023-09-27T19:32:33+00:00 https://biolegacyresearch.com/phrma-asks-fda-to-deny-florida-proposal-to-import-canadian-drugs/ 2023-09-27T20:00:26+00:00 https://biolegacyresearch.com/meeting-planner-week-of-sept-25-2023/ 2023-09-27T20:10:58+00:00 https://biolegacyresearch.com/adcomm-debates-clinical-data-vs-personal-data-in-decision-not-to-approve-als-stem-cell-therapy/ 2023-09-28T17:02:53+00:00 https://biolegacyresearch.com/quick-notes-for-sept-28-2023/ 2023-09-28T17:40:02+00:00 https://biolegacyresearch.com/fda-gives-guidance-on-gvhd-therapies-denovo-requests-device-closed-loop-controls-and-ast-system-devices/ 2023-09-28T19:31:08+00:00 https://biolegacyresearch.com/philips-responds-to-allegations-it-withheld-evidence-of-ventilator-malfunctions-for-11-years/ 2023-09-28T20:25:04+00:00 https://biolegacyresearch.com/no-actual-negotiation-in-ira-says-astrazeneca-in-motion-to-strike-down-law/ 2023-09-28T20:40:21+00:00 https://biolegacyresearch.com/regulatory-update-week-of-sept-25-2023/ 2023-09-29T17:43:40+00:00 https://biolegacyresearch.com/labeling-of-ready-to-use-prescription-drug-injectables-subject-of-fda-guidance/ 2023-09-29T18:00:05+00:00 https://biolegacyresearch.com/boehringer-ingelheim-seeks-summary-judgment-in-ira-lawsuit/ 2023-09-29T18:40:01+00:00 https://biolegacyresearch.com/government-shutdown-now-looks-inevitable-says-alliance-for-a-stronger-fda/ 2023-09-29T19:30:42+00:00 https://biolegacyresearch.com/renewing-the-debate-on-who-has-oversight-on-lab-tests-fda-proposes-new-rule/ 2023-09-29T20:20:24+00:00 https://biolegacyresearch.com/legislative-update-week-of-oct-2-2023/ 2023-10-02T18:51:28+00:00 https://biolegacyresearch.com/despite-new-guidance-manufacturers-lack-understanding-of-qrm-says-expert/ 2023-10-02T19:00:40+00:00 https://biolegacyresearch.com/lily-issued-third-complete-response-letter-in-2023-second-time-on-issues-related-to-manufacturing/ 2023-10-02T19:20:39+00:00 https://biolegacyresearch.com/dna-test-for-hundreds-of-cancer-variants-gets-fda-de-novo-marketing-authorization/ 2023-10-02T19:40:47+00:00 https://biolegacyresearch.com/quick-notes-warning-letters-oct-2-2023/ 2023-10-02T20:10:19+00:00 https://biolegacyresearch.com/drugmakers-go-two-and-two-with-recent-fda-decisions/ 2023-10-03T18:25:59+00:00 https://biolegacyresearch.com/fda-manual-of-policies-and-procedures-updates-anda-suitability-petitions/ 2023-10-03T18:40:13+00:00 https://biolegacyresearch.com/lilly-to-acquire-point-biopharma-for-1-4b-to-expand-oncology-capabilities/ 2023-10-03T19:05:22+00:00 https://biolegacyresearch.com/biosimilars-face-hurdles-of-clinician-patient-acceptance-after-gaining-fda-approval/ 2023-10-03T19:15:02+00:00 https://biolegacyresearch.com/digital-health-tech-study-results-show-difficulty-of-demonstrating-value/ 2023-10-03T19:30:33+00:00 https://biolegacyresearch.com/fda-publishes-guidance-on-oct-1-estar-requirement-updates-tplc-pilot/ 2023-10-04T18:01:01+00:00 https://biolegacyresearch.com/meeting-planner-week-of-oct-2-2023/ 2023-10-04T18:30:02+00:00 https://biolegacyresearch.com/fda-draft-guidance-pushes-for-development-of-stimulant-use-disorder-treatments/ 2023-10-04T18:45:34+00:00 https://biolegacyresearch.com/sanofi-and-teva-team-up-to-deliver-ibd-treatment/ 2023-10-04T19:00:27+00:00 https://biolegacyresearch.com/patent-board-sides-with-novo-nordisk-on-semaglutide-challenge-from-generic-maker-viatris/ 2023-10-04T20:20:53+00:00 https://biolegacyresearch.com/jama-study-highlights-increased-gastrointestinal-risks-of-popular-glp-1-agonists/ 2023-10-05T16:20:00+00:00 https://biolegacyresearch.com/controversial-approval-at-oncology-adcomm-for-us-worldmeds-dfmo-for-pediatric-neuroblastoma/ 2023-10-05T16:50:15+00:00 https://biolegacyresearch.com/fdanews-gmp-quality-management-vsummit-to-dovetail-with-industrys-hot-topics-says-conference-lead/ 2023-10-05T18:00:19+00:00 https://biolegacyresearch.com/pharma-groups-form-coalition-to-combat-ftc-approach-to-antitrust-enforcement/ 2023-10-05T18:30:07+00:00 https://biolegacyresearch.com/myriad-cgmp-lapses-found-during-fda-inspection-of-api-maker/ 2023-10-05T19:00:40+00:00 https://biolegacyresearch.com/fdas-odac-deems-sotorasibs-confirmatory-trial-too-troubled-to-be-interpreted/ 2023-10-06T17:56:50+00:00 https://biolegacyresearch.com/pre-bunking-potential-misunderstanding-of-science-is-key-for-fda-report-says/ 2023-10-06T18:40:05+00:00 https://biolegacyresearch.com/combination-product-regulations-standards-confounding-to-manufacturers-expert-says/ 2023-10-06T19:20:43+00:00 https://biolegacyresearch.com/fda-unsatisfied-with-philips-handling-of-massive-2021-recall/ 2023-10-06T19:47:56+00:00 https://biolegacyresearch.com/cancer-drugs-remain-in-short-supply-living-paycheck-to-paycheck-survey-says/ 2023-10-06T20:15:23+00:00 https://biolegacyresearch.com/legislative-update-week-of-oct-9-2023/ 2023-10-09T16:29:32+00:00 https://biolegacyresearch.com/fda-it-modernization-plan-prioritizes-data-sharing-ai-collaboration-and-more/ 2023-10-09T17:30:46+00:00 https://biolegacyresearch.com/alnylam-to-pull-expanded-indication-for-onpattro-after-crl/ 2023-10-09T18:49:34+00:00 https://biolegacyresearch.com/bristol-myers-squibb-snaps-up-mirati-and-its-kras-targeting-cancer-pipeline/ 2023-10-09T19:15:03+00:00 https://biolegacyresearch.com/speedier-approval-is-goal-of-fda-revision-of-mapp-for-anda-assessment-practices/ 2023-10-09T19:35:20+00:00 https://biolegacyresearch.com/pfizer-gets-interchangeable-designation-for-humira-biosimilar/ 2023-10-10T19:11:02+00:00 https://biolegacyresearch.com/quick-notes-oct-10-2023/ 2023-10-10T19:40:36+00:00 https://biolegacyresearch.com/histosonics-gets-fda-nod-for-breakthrough-device-that-destroys-liver-tumors/ 2023-10-10T19:58:26+00:00 https://biolegacyresearch.com/court-grants-injunction-against-eoflow-in-ongoing-insulin-pump-litigation/ 2023-10-10T20:15:47+00:00 https://biolegacyresearch.com/most-critical-care-ai-predictive-devices-come-to-market-lacking-supportive-data-study-says/ 2023-10-10T20:30:39+00:00 https://biolegacyresearch.com/fda-seeking-members-for-new-digital-health-advisory-committee/ 2023-10-11T17:17:31+00:00 https://biolegacyresearch.com/meeting-planner-week-of-oct-9-2023/ 2023-10-11T18:05:16+00:00 https://biolegacyresearch.com/failure-to-get-premarket-approval-for-impella-system-nets-abiomed-warning-letter/ 2023-10-11T19:15:26+00:00 https://biolegacyresearch.com/improved-industry-agility-in-quality-management-contingent-on-global-regulatory-framework-says-cder-official/ 2023-10-11T20:25:16+00:00 https://biolegacyresearch.com/burden-of-qmm-breadth-on-individual-companies-say-merck-experts/ 2023-10-11T21:04:13+00:00 https://biolegacyresearch.com/fda-shares-quality-considerations-for-ophthalmic-drugs-in-draft-guidance/ 2023-10-12T17:43:45+00:00 https://biolegacyresearch.com/vip-initiative-for-medical-devices-delivers-benefits-to-companies-beyond-just-compliance/ 2023-10-12T19:41:04+00:00 https://biolegacyresearch.com/european-commission-orders-illumina-to-unwind-grail-acquisition/ 2023-10-12T20:00:38+00:00 https://biolegacyresearch.com/alvotech-gets-4th-fda-complete-response-letter-this-time-for-stelara-biosimilar/ 2023-10-12T20:05:38+00:00 https://biolegacyresearch.com/combination-products-require-unique-risk-benefit-analysis-says-industry-expert/ 2023-10-12T20:10:38+00:00 https://biolegacyresearch.com/uk-accelerates-review-times-for-postmarket-certain-phase-3-trial-applications/ 2023-10-13T15:12:41+00:00 https://biolegacyresearch.com/regulatory-update-week-of-oct-9-2023/ 2023-10-13T15:18:10+00:00 https://biolegacyresearch.com/sample-sizes-need-to-be-larger-to-satisfy-fda-expectations-expert-says/ 2023-10-13T16:11:27+00:00 https://biolegacyresearch.com/phrma-files-amicus-brief-in-potential-supreme-court-mifepristone-case/ 2023-10-13T18:14:27+00:00 https://biolegacyresearch.com/qmsr-to-incorporate-iso-13485-fda-satellite-rules-by-reference-expert-explains/ 2023-10-13T21:57:03+00:00 https://biolegacyresearch.com/legislative-update-week-of-oct-16-2023/ 2023-10-16T18:20:23+00:00 https://biolegacyresearch.com/guidance-alerts-drugmakers-to-health-hazard-of-methanol-contamination/ 2023-10-16T18:40:48+00:00 https://biolegacyresearch.com/fda-shares-clinical-trial-considerations-for-diabetic-foot-infection-drugs/ 2023-10-16T19:30:10+00:00 https://biolegacyresearch.com/cms-policy-change-will-allow-coverage-of-multiple-pet-scans-to-detect-alzheimers-plaque/ 2023-10-16T20:00:17+00:00 https://biolegacyresearch.com/former-ceo-pleads-guilty-to-marketing-unapproved-medical-device/ 2023-10-16T20:07:58+00:00 https://biolegacyresearch.com/capa-verification-of-effectiveness-lessons-from-experts-in-a-two-part-series/ 2023-10-17T17:31:56+00:00 https://biolegacyresearch.com/novo-nordisk-to-acquire-ocedurenone-from-kbp-biosciences-for-1-3b/ 2023-10-17T17:35:11+00:00 https://biolegacyresearch.com/three-new-keytruda-indications-among-mid-october-approvals/ 2023-10-17T18:52:59+00:00 https://biolegacyresearch.com/illumina-goes-to-battle-against-ec-order-to-unwind-acquisition-of-grail/ 2023-10-17T19:59:19+00:00 https://biolegacyresearch.com/simplicity-is-cornerstone-of-ongoing-process-improvement-says-expert/ 2023-10-17T20:15:42+00:00 https://biolegacyresearch.com/fda-clarifies-risk-benefit-assessment-during-pre-and-postmarket-considerations/ 2023-10-18T17:30:52+00:00 https://biolegacyresearch.com/meeting-planner-week-of-oct-16-2023/ 2023-10-18T17:50:03+00:00 https://biolegacyresearch.com/remote-patient-monitoring-device-guidance-gets-post-covid-update/ 2023-10-18T18:15:58+00:00 https://biolegacyresearch.com/cder-seeks-industry-feedback-on-clinical-trial-innovation/ 2023-10-18T18:40:25+00:00 https://biolegacyresearch.com/doj-lambasts-bristol-myers-squibb-johnson-johnson-lawsuits-against-ira/ 2023-10-18T19:52:43+00:00 https://biolegacyresearch.com/fda-guidance-describes-voluntary-consensus-standards-for-regenerative-therapy/ 2023-10-19T18:32:02+00:00 https://biolegacyresearch.com/in-stunning-turnaround-embattled-tenapanor-gets-fda-approval-following-crl/ 2023-10-19T18:33:33+00:00 https://biolegacyresearch.com/fda-slaps-samsung-biologics-with-form-483-over-data-integrity-issues-quality-lapses/ 2023-10-19T20:18:11+00:00 https://biolegacyresearch.com/hamilton-ventilator-recall-deemed-class-i-for-potential-leak-onto-control-board/ 2023-10-19T20:20:10+00:00 https://biolegacyresearch.com/brainstorm-to-withdraw-nurown-bla-for-treatment-of-als/ 2023-10-19T20:24:25+00:00 https://biolegacyresearch.com/quick-notes-eu-edition-oct-20-2023/ 2023-10-20T17:39:48+00:00 https://biolegacyresearch.com/regulatory-update-week-of-oct-16-2023/ 2023-10-20T17:41:19+00:00 https://biolegacyresearch.com/lilly-files-more-lawsuits-against-pharmacies-selling-knockoff-mounjaro-alerts-itc/ 2023-10-20T19:10:00+00:00 https://biolegacyresearch.com/acquisitions-and-collaborations-hot-for-pfizer-thermo-fisher-merck-and-daiichi-sankyo/ 2023-10-20T19:30:06+00:00 https://biolegacyresearch.com/biocon-biologics-draws-fda-oai-classification-nectar-gets-untitled-letter/ 2023-10-20T19:55:16+00:00 https://biolegacyresearch.com/legislative-update-week-of-oct-23-2023/ 2023-10-23T17:53:18+00:00 https://biolegacyresearch.com/quick-notes-for-oct-23-2023/ 2023-10-23T18:50:59+00:00 https://biolegacyresearch.com/communications-on-unapproved-use-of-approved-products-is-focus-of-draft-guidance/ 2023-10-23T19:10:56+00:00 https://biolegacyresearch.com/medtech-trade-groups-warn-of-disastrous-impact-from-proposed-eto-regulations/ 2023-10-23T20:19:39+00:00 https://biolegacyresearch.com/poor-aseptic-technique-nets-indian-vaccine-maker-panacea-biotec-a-form-483/ 2023-10-23T20:24:25+00:00 https://biolegacyresearch.com/eu-medical-device-guidance-addresses-data-collection-software-requirements/ 2023-10-24T19:29:30+00:00 https://biolegacyresearch.com/capa-verification-of-effectiveness-understanding-key-voe-principles/ 2023-10-24T19:49:00+00:00 https://biolegacyresearch.com/form-483-responses-must-be-well-organized-and-include-adequate-corrective-actions-says-fda-official/ 2023-10-24T19:55:00+00:00 https://biolegacyresearch.com/guiding-principles-for-ai-ml-technologies-outlined-by-the-u-s-canada-and-uk/ 2023-10-24T20:05:52+00:00 https://biolegacyresearch.com/sanofi-and-regeneron-get-crl-for-dupixent-sbla/ 2023-10-24T20:15:11+00:00 https://biolegacyresearch.com/meeting-planner-week-of-oct-23-2023/ 2023-10-25T19:06:17+00:00 https://biolegacyresearch.com/drug-facility-remote-inspections-is-focus-of-draft-guidance/ 2023-10-25T19:25:00+00:00 https://biolegacyresearch.com/fda-deems-olympus-insufflation-and-fresenius-hemodialysis-device-recalls-as-class-i/ 2023-10-25T19:45:00+00:00 https://biolegacyresearch.com/every-aspect-of-clinical-trials-needs-rethinking-to-achieve-wide-participation-says-expert/ 2023-10-25T20:10:07+00:00 https://biolegacyresearch.com/fda-slaps-switzerlands-ucb-farchim-with-form-483-over-quality-deficiencies/ 2023-10-25T20:45:21+00:00 https://biolegacyresearch.com/quick-notes-for-oct-26-2023/ 2023-10-26T16:49:02+00:00 https://biolegacyresearch.com/corticosteroid-bioequivalence-draft-guidance-developed-to-replace-1995-version/ 2023-10-26T17:30:52+00:00 https://biolegacyresearch.com/lower-value-cancer-drugs-prescribed-more-often-when-docs-are-paid-study-says/ 2023-10-26T17:45:31+00:00 https://biolegacyresearch.com/fda-issues-warning-letter-to-abbott-labs-over-infant-probiotic-marketing/ 2023-10-26T20:00:50+00:00 https://biolegacyresearch.com/bernie-sanders-questions-nih-proposal-to-give-obscure-company-an-exclusive-patent-license-for-cancer-drug/ 2023-10-26T20:10:15+00:00 https://biolegacyresearch.com/new-database-describes-141-investigatory-alzheimers-drugs-187-global-clinical-trials/ 2023-10-27T18:00:45+00:00 https://biolegacyresearch.com/regulatory-update-week-of-oct-23-2023/ 2023-10-27T18:30:01+00:00 https://biolegacyresearch.com/importation-of-apple-watches-banned-by-itc-in-masimo-patent-dispute/ 2023-10-27T18:45:44+00:00 https://biolegacyresearch.com/b-braun-infusion-pump-cardinal-health-syringes-see-recalls-deemed-class-i/ 2023-10-27T19:00:09+00:00 https://biolegacyresearch.com/government-shutdown-unlikely-but-key-challenges-remain-says-fda-advocacy-expert/ 2023-10-27T20:15:39+00:00 https://biolegacyresearch.com/legislative-update-week-of-oct-30-2023/ 2023-10-30T17:43:06+00:00 https://biolegacyresearch.com/fda-inspections-look-hard-at-reporting-structure-quality-staff-former-investigator-says/ 2023-10-30T19:05:07+00:00 https://biolegacyresearch.com/listening-sessions-offer-patients-chance-to-talk-about-ira-top-10-drugs/ 2023-10-30T19:15:58+00:00 https://biolegacyresearch.com/white-house-executive-order-tackles-ai-safety-transparency/ 2023-10-30T19:30:39+00:00 https://biolegacyresearch.com/fda-adcomm-will-review-vertexs-off-target-effects-data-for-sickle-cell-gene-therapy/ 2023-10-30T20:49:35+00:00 https://biolegacyresearch.com/extent-of-cms-coverage-for-leqembi-treatment-still-uncertain-clinicians-say/ 2023-10-31T18:00:13+00:00 https://biolegacyresearch.com/viewpoint-fda-needs-to-take-direct-action-to-combat-effects-of-medical-misinformation/ 2023-10-31T18:30:12+00:00 https://biolegacyresearch.com/lilly-beam-therapeutics-forge-600m-deal-on-gene-editing-programs/ 2023-10-31T19:21:55+00:00 https://biolegacyresearch.com/quick-notes-for-oct-31-2023/ 2023-10-31T20:00:37+00:00 https://biolegacyresearch.com/nostrum-labs-agrees-to-pay-up-to-50-million-over-underpayment-of-medicaid-rebates/ 2023-10-31T20:20:18+00:00 https://biolegacyresearch.com/fda-extends-covid-era-requirements-for-changes-to-a-device-under-pma-or-hde/ 2023-11-01T17:20:21+00:00 https://biolegacyresearch.com/meeting-planner-week-of-oct-30-2023/ 2023-11-01T19:05:19+00:00 https://biolegacyresearch.com/cber-crowdsourcing-campaign-seeks-stakeholder-input-on-future-trends/ 2023-11-01T19:40:20+00:00 https://biolegacyresearch.com/sarepta-downplays-negative-results-to-pursue-expanded-indication-for-duchenne-therapy/ 2023-11-01T20:40:40+00:00 https://biolegacyresearch.com/vertex-gets-safety-go-ahead-for-sickle-cell-gene-editing-treatment/ 2023-11-01T21:20:02+00:00 https://biolegacyresearch.com/biotech-sector-continues-rise-taking-one-third-of-pharma-market-in-2023/ 2023-11-02T19:29:26+00:00 https://biolegacyresearch.com/fda-beats-alvogen-suit-over-xifaxan-skinny-label-rejection/ 2023-11-02T20:00:04+00:00 https://biolegacyresearch.com/clinical-electronic-thermometers-guidance-makes-fda-covid-era-policy-permanent/ 2023-11-02T20:15:35+00:00 https://biolegacyresearch.com/cardinal-health-and-harvard-drug-group-recall-velocity-pharma-produced-otc-eye-drops/ 2023-11-02T20:30:18+00:00 https://biolegacyresearch.com/quick-notes-for-nov-2-2023/ 2023-11-02T20:45:13+00:00 https://biolegacyresearch.com/regulatory-update-week-of-oct-30-2023/ 2023-11-03T17:14:24+00:00 https://biolegacyresearch.com/how-postpandemic-inspections-could-impact-approvals/ 2023-11-03T17:50:19+00:00 https://biolegacyresearch.com/research-round-up-november-2023/ 2023-11-03T20:00:13+00:00 https://biolegacyresearch.com/house-and-senate-still-far-apart-on-fda-appropriations/ 2023-11-03T20:15:41+00:00 https://biolegacyresearch.com/fda-slaps-natco-with-form-483-over-contamination-issues-quality-lapses/ 2023-11-03T20:30:22+00:00 https://biolegacyresearch.com/legislative-update-week-of-nov-6-2023/ 2023-11-06T18:56:19+00:00 https://biolegacyresearch.com/european-pharma-predicted-to-lose-a-third-of-its-global-rd-with-proposed-legislation/ 2023-11-06T20:23:58+00:00 https://biolegacyresearch.com/fda-panel-will-make-classification-recommendations-on-blood-irradiators/ 2023-11-06T20:26:10+00:00 https://biolegacyresearch.com/fda-publishes-two-final-guidances-on-technical-specifications-for-clinical-data/ 2023-11-06T20:47:35+00:00 https://biolegacyresearch.com/house-committee-demands-answers-meeting-with-fda-on-drug-shortages/ 2023-11-06T20:55:43+00:00 https://biolegacyresearch.com/ftc-challenges-accuracy-of-100-patents-held-by-10-large-drugmakers/ 2023-11-07T20:26:32+00:00 https://biolegacyresearch.com/cms-proposes-allowing-medicare-coverage-of-biosimilars-without-interchangeable-status/ 2023-11-07T20:34:04+00:00 https://biolegacyresearch.com/intarcia-appeals-fda-panel-decision-on-diabetes-product-citing-misleading-claims/ 2023-11-07T21:06:52+00:00 https://biolegacyresearch.com/final-guidances-available-on-real-time-oncology-review-exporting-devices/ 2023-11-07T22:09:32+00:00 https://biolegacyresearch.com/quick-notes-for-nov-7-2023/ 2023-11-07T22:11:49+00:00 https://biolegacyresearch.com/meeting-planner-week-of-nov-6-2023/ 2023-11-08T18:30:00+00:00 https://biolegacyresearch.com/25-attorneys-general-seek-warnings-on-pulse-oximeters-based-on-skin-tone/ 2023-11-08T19:29:39+00:00 https://biolegacyresearch.com/catheter-kit-recall-deemed-class-i-company-recalls-irrigation-water-for-sterility-issue/ 2023-11-08T19:32:28+00:00 https://biolegacyresearch.com/glass-vials-and-stoppers-closure-system-and-component-changes-guidance-extended/ 2023-11-08T19:40:41+00:00 https://biolegacyresearch.com/ora-reorganization-could-boost-inspection-outcomes-says-regulatory-expert/ 2023-11-08T20:24:06+00:00 https://biolegacyresearch.com/senate-committee-passes-bill-for-legislative-improvements-to-pbm-landscape/ 2023-11-09T18:51:15+00:00 https://biolegacyresearch.com/ich-adopts-guideline-on-viral-safety-evaluation-of-biotechnology-products/ 2023-11-09T19:46:11+00:00 https://biolegacyresearch.com/long-lasting-insulin-levemir-to-be-pulled-from-market-by-novo-nordisk/ 2023-11-09T19:55:43+00:00 https://biolegacyresearch.com/dream-sock-baby-monitor-renal-denervation-to-control-blood-pressure-get-fda-nods/ 2023-11-09T19:59:38+00:00 https://biolegacyresearch.com/false-or-misleading-claims-get-rexulti-and-phexxi-fda-untitled-letters/ 2023-11-09T20:26:51+00:00 https://biolegacyresearch.com/regulatory-update-week-of-nov-6-2023/ 2023-11-10T19:00:01+00:00 https://biolegacyresearch.com/health-policy-groups-file-amicus-briefs-supporting-ira-in-ongoing-astrazeneca-lawsuit/ 2023-11-10T19:30:50+00:00 https://biolegacyresearch.com/quality-agreements-must-establish-major-supplier-responsibilities-says-expert/ 2023-11-10T20:04:00+00:00 https://biolegacyresearch.com/once-temporary-remote-inspection-tools-are-now-part-of-everyday-regulatory-life/ 2023-11-10T20:15:56+00:00 https://biolegacyresearch.com/quick-notes-european-edition-nov-10-2023/ 2023-11-10T20:20:31+00:00 https://biolegacyresearch.com/legislative-update-week-of-nov-13-2023/ 2023-11-13T18:52:16+00:00 https://biolegacyresearch.com/revamped-capa-process-has-reduced-timelines-by-50-percent-fda-says/ 2023-11-13T19:41:30+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-nov-13-2023/ 2023-11-13T20:19:40+00:00 https://biolegacyresearch.com/using-collaboration-and-ai-to-repurpose-already-approved-medications-for-new-indications/ 2023-11-13T20:46:28+00:00 https://biolegacyresearch.com/draft-guidance-changes-could-stifle-innovation-in-cell-and-gene-therapies-commentors-say/ 2023-11-13T22:32:02+00:00 https://biolegacyresearch.com/recall-of-stolen-defective-medtronic-laryngoscopes-deemed-class-i/ 2023-11-14T19:29:47+00:00 https://biolegacyresearch.com/americas-disappearing-pharmacies-and-the-fdas-role-in-supporting-access-to-rx/ 2023-11-14T20:27:42+00:00 https://biolegacyresearch.com/bayer-withdraws-aliqopa-after-missing-confirmatory-trial-endpoint/ 2023-11-14T20:28:08+00:00 https://biolegacyresearch.com/accord-receives-fda-go-ahead-for-cisplatin-methotrexate-sales-in-u-s/ 2023-11-14T20:28:37+00:00 https://biolegacyresearch.com/iqvia-battles-ftcs-efforts-to-thwart-acquisition-of-propel-media/ 2023-11-14T21:05:12+00:00 https://biolegacyresearch.com/fda-warns-eye-drop-manufacturer-for-sterility-lapses-resulting-in-blindness-death/ 2023-11-15T18:09:10+00:00 https://biolegacyresearch.com/meeting-planner-week-of-nov-13-2023/ 2023-11-15T18:45:22+00:00 https://biolegacyresearch.com/califf-presents-recommendations-for-improving-the-postmarket-drug-evaluation-system/ 2023-11-15T19:00:15+00:00 https://biolegacyresearch.com/olympus-bronchoscopes-risk-for-endobronchial-combustion-has-recall-deemed-class-i/ 2023-11-15T20:54:16+00:00 https://biolegacyresearch.com/fda-pivots-to-enforcement-of-udi-requirements/ 2023-11-15T21:33:01+00:00 https://biolegacyresearch.com/worlds-first-crispr-based-gene-therapy-authorized-by-uks-mhra/ 2023-11-16T18:27:55+00:00 https://biolegacyresearch.com/new-and-revised-product-specific-guidelines-include-semaglutide-gabapentin-albuterol/ 2023-11-16T19:37:18+00:00 https://biolegacyresearch.com/arizona-company-settles-doj-charges-of-selling-unapproved-contraceptive-cream/ 2023-11-16T20:15:02+00:00 https://biolegacyresearch.com/quick-notes-medical-devices-nov-16-2023/ 2023-11-16T21:20:21+00:00 https://biolegacyresearch.com/oncology-drugs-used-for-a-decade-need-focused-confirmatory-trials-adcomm-says/ 2023-11-16T22:39:32+00:00 https://biolegacyresearch.com/regulatory-update-week-of-nov-13-2023/ 2023-11-17T18:41:53+00:00 https://biolegacyresearch.com/equipment-and-facility-cleanliness-nets-dr-reddys-a-form-483/ 2023-11-17T20:09:14+00:00 https://biolegacyresearch.com/robotic-surgical-system-recalled-due-to-malfunctions-with-unintended-movement/ 2023-11-17T20:45:57+00:00 https://biolegacyresearch.com/medical-companies-cheat-more-on-patents-than-other-industries-study-shows/ 2023-11-17T21:00:21+00:00 https://biolegacyresearch.com/quick-notes-for-nov-17-2023/ 2023-11-17T21:25:46+00:00 https://biolegacyresearch.com/faulty-alarm-that-can-stop-medication-infusion-costs-b-braun-pump-a-class-i-recall/ 2023-11-20T19:57:00+00:00 https://biolegacyresearch.com/legislative-update-week-of-nov-20-2023/ 2023-11-20T20:05:21+00:00 https://biolegacyresearch.com/nhs-drugmakers-agree-to-deal-that-saves-uk-health-system-17b/ 2023-11-20T20:10:55+00:00 https://biolegacyresearch.com/mercks-second-try-with-gefapixant-is-another-regulatory-no-go/ 2023-11-20T20:15:46+00:00 https://biolegacyresearch.com/understanding-drugs-risks-is-focus-of-fda-final-rule-on-dtc-drug-ads/ 2023-11-20T20:20:31+00:00 https://biolegacyresearch.com/inspection-review-activities-undergo-change-in-two-sweeping-fda-reorganizations/ 2023-11-21T18:55:49+00:00 https://biolegacyresearch.com/biosimilars-show-no-difference-in-safety-immunogenicity-says-fda-statistical-review/ 2023-11-21T19:10:13+00:00 https://biolegacyresearch.com/ftc-weighs-in-on-improper-orange-book-patent-listings-in-viatris-sanofi-dispute/ 2023-11-21T19:25:21+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-nov-21-2023/ 2023-11-21T19:44:17+00:00 https://biolegacyresearch.com/rare-cancer-drugs-carry-unique-fda-postmarketing-requirements-say-scholars/ 2023-11-22T17:14:52+00:00 https://biolegacyresearch.com/quick-notes-nov-22-2023/ 2023-11-22T17:25:00+00:00 https://biolegacyresearch.com/research-roundup-november-2023/ 2023-11-22T17:35:00+00:00 https://biolegacyresearch.com/meeting-planner-week-of-nov-20-2023/ 2023-11-22T17:45:00+00:00 https://biolegacyresearch.com/why-lot-size-doesnt-matter-when-choosing-a-sample-size/ 2023-11-22T17:45:04+00:00 https://biolegacyresearch.com/legislative-update-week-of-nov-27-2023/ 2023-11-27T18:55:00+00:00 https://biolegacyresearch.com/fda-withdraws-from-global-harmonization-group-announces-surveys-on-service-levels/ 2023-11-27T19:20:45+00:00 https://biolegacyresearch.com/uks-new-eligibility-checker-can-speed-drug-application-process/ 2023-11-27T19:40:32+00:00 https://biolegacyresearch.com/quick-notes-nov-27-2023/ 2023-11-27T20:10:38+00:00 https://biolegacyresearch.com/final-guidance-stresses-covid-19-drug-trials-among-elderly-and-in-nursing-homes/ 2023-11-27T20:50:42+00:00 https://biolegacyresearch.com/fda-requests-new-trial-for-aldeyra-therapeutics-dry-eye-disease-drug/ 2023-11-28T19:40:55+00:00 https://biolegacyresearch.com/biden-announces-drug-supply-chain-fixes-think-tank-says-government-isnt-doing-enough/ 2023-11-28T21:25:00+00:00 https://biolegacyresearch.com/cybersecurity-event-disrupts-it-systems-for-devicemaker-livanova/ 2023-11-28T21:35:00+00:00 https://biolegacyresearch.com/intas-slapped-with-fda-warning-letter-import-alert-for-cgmp-violations/ 2023-11-28T21:42:58+00:00 https://biolegacyresearch.com/quick-notes-nov-28-2023/ 2023-11-28T22:00:00+00:00 https://biolegacyresearch.com/fda-investigating-risk-of-t-cell-malignancy-from-car-t-cell-immunotherapies/ 2023-11-29T19:16:19+00:00 https://biolegacyresearch.com/meeting-planner-week-of-nov-27-2023/ 2023-11-29T19:30:56+00:00 https://biolegacyresearch.com/vivos-gets-fda-nod-for-sleep-apnea-oral-device-while-philips-wrestles-with-yet-another-cpap-safety-issue/ 2023-11-29T19:40:22+00:00 https://biolegacyresearch.com/fda-proposes-pma-and-new-classifications-for-certain-wound-dressings-washes/ 2023-11-29T19:50:17+00:00 https://biolegacyresearch.com/experts-fda-debate-mortality-as-endpoint-for-multi-cancer-diagnostic-trials/ 2023-11-29T22:18:42+00:00 https://biolegacyresearch.com/novo-nordisk-fights-fake-wegovy-ozempic-and-faces-mounjaros-superior-study-results/ 2023-11-30T18:50:07+00:00 https://biolegacyresearch.com/adcomm-cautions-on-social-emotional-risks-associated-with-multi-cancer-screening/ 2023-11-30T19:10:53+00:00 https://biolegacyresearch.com/lack-of-sterility-lab-controls-earns-kilitch-healthcare-a-form-483/ 2023-11-30T19:30:19+00:00 https://biolegacyresearch.com/abbvie-plans-10-1b-acquisition-of-immunogen-to-speed-entry-into-ovarian-cancer-market/ 2023-11-30T20:35:51+00:00 https://biolegacyresearch.com/fda-chief-scientist-namandje-bumpus-named-to-replace-janet-woodcock/ 2023-11-30T20:45:00+00:00 https://biolegacyresearch.com/eitan-medical-recalls-infusion-pumps-for-failure-to-detect-air-in-the-line/ 2023-12-01T20:45:45+00:00 https://biolegacyresearch.com/regulatory-update-week-of-nov-27-2023/ 2023-12-01T20:55:40+00:00 https://biolegacyresearch.com/device-failures-lead-fda-to-urge-avoiding-plastic-syringes-made-in-china/ 2023-12-01T20:55:41+00:00 https://biolegacyresearch.com/europes-mdcg-presses-device-manufacturers-to-get-certified-asap/ 2023-12-01T21:05:08+00:00 https://biolegacyresearch.com/weight-loss-drug-market-looks-to-expand-while-ema-expands-review-of-glp-1-agonists-and-suicide/ 2023-12-01T21:56:10+00:00 https://biolegacyresearch.com/legislative-update-week-of-dec-4-2023/ 2023-12-04T19:37:46+00:00 https://biolegacyresearch.com/fda-announces-reorganization-of-two-cber-offices/ 2023-12-04T20:30:17+00:00 https://biolegacyresearch.com/four-class-i-recalls-span-tainted-glucose-capsules-infusion-devices-eye-drops/ 2023-12-04T20:55:17+00:00 https://biolegacyresearch.com/thousands-of-comments-pour-in-on-fda-plan-to-regulate-laboratory-developed-tests/ 2023-12-04T22:43:21+00:00 https://biolegacyresearch.com/three-healthcare-titans-make-deals-to-expand-their-portfolios/ 2023-12-04T22:55:52+00:00 https://biolegacyresearch.com/fdas-marks-weighs-ups-and-downs-of-gene-therapy-during-alliance-webinar/ 2023-12-05T20:20:03+00:00 https://biolegacyresearch.com/house-subcommittee-asks-fda-for-briefing-on-ineffective-otc-drugs/ 2023-12-05T20:30:46+00:00 https://biolegacyresearch.com/quick-notes-for-dec-5-2023-medical-devices/ 2023-12-05T20:40:37+00:00 https://biolegacyresearch.com/astrazeneca-continues-bitter-fight-over-iras-drug-price-negotiations/ 2023-12-05T20:50:23+00:00 https://biolegacyresearch.com/drug-quality-assurance-inspections-are-still-far-below-pre-pandemic-rates-study-says/ 2023-12-05T21:05:18+00:00 https://biolegacyresearch.com/meeting-planner-week-of-dec-4-2023/ 2023-12-06T19:20:43+00:00 https://biolegacyresearch.com/drug-manufacturers-accuse-uk-government-of-sending-industry-mixed-messages/ 2023-12-06T19:40:41+00:00 https://biolegacyresearch.com/cordis-recall-of-angiographic-catheter-for-lack-of-sterilization-deemed-class-i/ 2023-12-06T20:00:43+00:00 https://biolegacyresearch.com/fda-updates-electronic-submission-of-medical-device-applications-process/ 2023-12-06T20:20:48+00:00 https://biolegacyresearch.com/contaminated-containers-mold-steer-fda-to-untitled-letter-for-novartis-kymriah/ 2023-12-06T20:50:04+00:00 https://biolegacyresearch.com/medtronic-backs-out-of-738-million-eoflow-deal/ 2023-12-07T18:42:44+00:00 https://biolegacyresearch.com/abbvie-to-strengthen-neuroscience-pipeline-with-8-7-billion-for-cerevel-therapeutics/ 2023-12-07T18:53:15+00:00 https://biolegacyresearch.com/advamed-industry-express-concerns-with-trio-of-fda-draft-device-guidances/ 2023-12-07T19:03:37+00:00 https://biolegacyresearch.com/high-cost-of-gene-therapy-draws-senate-attention-on-eve-of-exa-cel-pdufa-date/ 2023-12-07T20:09:23+00:00 https://biolegacyresearch.com/draft-guidances-describe-fdas-interim-plans-for-bulk-drugs-used-for-compounding/ 2023-12-07T20:11:51+00:00 https://biolegacyresearch.com/fda-warns-of-rare-but-serious-drug-reaction-to-the-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr-spritam-and-clobazam-onfi-sympazan/ 2023-12-08T14:07:15+00:00 https://biolegacyresearch.com/two-gene-therapies-to-treat-sickle-cell-get-landmark-fda-approval/ 2023-12-08T19:25:54+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-dec-7-2023/ 2023-12-08T19:35:04+00:00 https://biolegacyresearch.com/regulatory-update-week-of-dec-4-2023/ 2023-12-08T19:45:14+00:00 https://biolegacyresearch.com/white-house-signals-support-of-obscure-law-to-lower-prices-on-taxpayer-funded-drugs/ 2023-12-08T20:05:55+00:00 https://biolegacyresearch.com/devicemaker-ivdr-application-foot-dragging-shown-in-team-nb-survey/ 2023-12-08T20:10:34+00:00 https://biolegacyresearch.com/legislative-update-week-of-dec-11-2023/ 2023-12-11T18:31:04+00:00 https://biolegacyresearch.com/hhs-releases-fall-2023-unified-agenda/ 2023-12-11T20:35:00+00:00 https://biolegacyresearch.com/teva-petitions-federal-judge-in-colorado-to-reject-motion-to-dismiss-epi-pen-lawsuit/ 2023-12-11T21:37:55+00:00 https://biolegacyresearch.com/price-hikes-for-8-of-10-high-cost-drugs-not-supported-by-new-evidence-says-icer/ 2023-12-11T21:47:49+00:00 https://biolegacyresearch.com/getinge-recall-of-cardiohelp-emergency-drive-deemed-class-i-by-fda/ 2023-12-11T21:55:00+00:00 https://biolegacyresearch.com/advamed-announces-new-medical-imaging-technology-division/ 2023-12-12T20:10:31+00:00 https://biolegacyresearch.com/ftc-issues-complaint-against-sanofi-maze-acquisition-deal-sanofi-caves/ 2023-12-12T20:40:44+00:00 https://biolegacyresearch.com/peptide-guidance-comments-stress-categorization-immune-responses/ 2023-12-12T20:50:23+00:00 https://biolegacyresearch.com/bidens-price-controls-will-hinder-u-s-clinical-research-chamber-of-commerce-says/ 2023-12-12T20:55:05+00:00 https://biolegacyresearch.com/advance-manufacturing-technologies-program-will-speed-drug-development-fda-says/ 2023-12-12T21:00:08+00:00 https://biolegacyresearch.com/pharma-questions-impurity-thresholds-in-topical-ophthalmic-drug-guidance/ 2023-12-13T18:14:11+00:00 https://biolegacyresearch.com/meeting-planner-week-of-dec-11-2023/ 2023-12-13T19:08:00+00:00 https://biolegacyresearch.com/bio-poll-shows-strong-support-among-voters-for-orphan-cures-act/ 2023-12-13T20:10:05+00:00 https://biolegacyresearch.com/quick-notes-for-dec-13-2023-european-edition/ 2023-12-13T20:35:29+00:00 https://biolegacyresearch.com/new-fda-advisory-committee-to-explore-genetic-metabolic-disease-drugs/ 2023-12-13T20:55:56+00:00 https://biolegacyresearch.com/international-regulations-governing-excipient-manufacturing-vary-widely/ 2023-12-14T17:45:21+00:00 https://biolegacyresearch.com/increased-prices-contributes-to-drug-spending-of-almost-406-billion-in-2022-cms-says/ 2023-12-14T18:25:17+00:00 https://biolegacyresearch.com/illumina-prepares-for-divestiture-of-grail/ 2023-12-14T18:45:45+00:00 https://biolegacyresearch.com/fda-joins-three-new-device-collaborations-including-global-ai-initiative/ 2023-12-14T20:55:43+00:00 https://biolegacyresearch.com/makers-of-48-drugs-raising-prices-faster-than-inflation-to-face-penalties-says-white-house/ 2023-12-14T22:05:43+00:00 https://biolegacyresearch.com/fda-updates-policy-on-anda-labeling-revisions/ 2023-12-15T18:10:23+00:00 https://biolegacyresearch.com/regulatory-update-week-of-dec-11-2023/ 2023-12-15T18:25:09+00:00 https://biolegacyresearch.com/pfizer-completes-43b-acquisition-of-seagen-after-donating-rights-to-cancer-drug/ 2023-12-15T18:45:47+00:00 https://biolegacyresearch.com/senators-ask-gao-to-review-fda-handling-of-medical-device-recalls/ 2023-12-15T19:10:12+00:00 https://biolegacyresearch.com/patient-voice-should-guide-clinical-trial-design-for-rare-disease-treatments/ 2023-12-15T19:25:35+00:00 https://biolegacyresearch.com/third-party-manufacturer-inspection-nets-checkpoint-therapeutics-a-crl/ 2023-12-18T19:45:39+00:00 https://biolegacyresearch.com/evaluation-of-rwd-rwe-for-medical-devices-is-subject-of-fda-draft-guidance/ 2023-12-18T19:55:07+00:00 https://biolegacyresearch.com/quick-notes-for-dec-18-2023-medical-devices/ 2023-12-18T20:05:16+00:00 https://biolegacyresearch.com/legislative-update-week-of-dec-18-2023/ 2023-12-18T20:15:17+00:00 https://biolegacyresearch.com/industry-calls-on-fda-to-be-more-detailed-on-rwd-in-confirmatory-evidence-guidance/ 2023-12-18T20:25:54+00:00 https://biolegacyresearch.com/ftc-doj-hhs-will-share-data-to-understand-corporate-powers-effect-on-health-care/ 2023-12-19T20:19:57+00:00 https://biolegacyresearch.com/fda-receives-support-concerns-over-proposed-quality-management-maturity-program/ 2023-12-19T20:20:23+00:00 https://biolegacyresearch.com/ema-publishes-ai-workplan-for-regulatory-oversight-through-2028/ 2023-12-19T20:21:27+00:00 https://biolegacyresearch.com/apple-watch-patent-battle-freezes-u-s-sales-awaiting-biden-decision/ 2023-12-19T20:29:51+00:00 https://biolegacyresearch.com/quick-notes-dec-19-2023/ 2023-12-19T20:48:21+00:00 https://biolegacyresearch.com/meeting-planner-week-of-dec-18-2023/ 2023-12-20T18:00:53+00:00 https://biolegacyresearch.com/olympus-bronchoscopes-recall-deemed-class-i-by-fda/ 2023-12-20T19:30:25+00:00 https://biolegacyresearch.com/fda-guidance-extends-covid-19-monoclonal-antibody-eua-policy-beyond-pandemic/ 2023-12-20T20:40:09+00:00 https://biolegacyresearch.com/quick-notes-for-dec-20-2023-medical-devices/ 2023-12-20T20:50:29+00:00 https://biolegacyresearch.com/team-nb-tackles-meaning-of-lifetime-for-medical-devices-in-new-position-paper/ 2023-12-21T17:25:50+00:00 https://biolegacyresearch.com/fda-slaps-fresenius-kabi-over-adulterated-devices-pcb-emissions-and-capa-lapses/ 2023-12-21T17:35:04+00:00 https://biolegacyresearch.com/fda-ema-answer-questions-about-breakthrough-medicines-manufacturing/ 2023-12-21T18:00:50+00:00 https://biolegacyresearch.com/fda-outlines-expectations-for-third-party-510k-and-eua-reviews/ 2023-12-21T18:15:27+00:00 https://biolegacyresearch.com/fda-shares-adaptive-design-for-highly-variable-drug-bioequivalence-studies/ 2023-12-21T18:30:01+00:00 https://biolegacyresearch.com/ultragenyx-agrees-to-6m-settlement-over-kickback-allegations/ 2023-12-26T18:34:28+00:00 https://biolegacyresearch.com/bms-spends-14-billion-to-buy-karuna-therapeutics-and-novel-action-antipsychotic/ 2023-12-26T18:36:46+00:00 https://biolegacyresearch.com/150-philips-mri-scanners-subject-to-class-1-recall-for-explosion-risk/ 2023-12-26T19:06:25+00:00 https://biolegacyresearch.com/merck-zealand-get-crls-for-investigational-products/ 2023-12-26T20:42:21+00:00 https://biolegacyresearch.com/fda-finalizes-numerous-guidances-issues-new-master-protocol-guidance/ 2023-12-26T20:46:00+00:00 https://biolegacyresearch.com/in-bid-to-keep-selling-watches-apple-appeals-federal-import-and-sales-ban/ 2023-12-27T17:29:56+00:00 https://biolegacyresearch.com/quick-notes-dec-27-2023/ 2023-12-27T18:50:44+00:00 https://biolegacyresearch.com/coherus-bounces-back-with-approval-of-udenyca-onbody-post-chemo-drug-device/ 2023-12-27T18:53:43+00:00 https://biolegacyresearch.com/fda-guidances-clarify-testing-for-benzene-quality-considerations-for-ophthalmic-drugs/ 2023-12-27T18:56:21+00:00 https://biolegacyresearch.com/amazon-gets-third-fda-warning-letter-of-2023-named-in-five-others/ 2023-12-28T15:48:47+00:00 https://biolegacyresearch.com/research-report-december-2023/ 2023-12-28T16:24:56+00:00 https://biolegacyresearch.com/fda-cisa-should-update-medical-device-cybersecurity-agreement-gao-says/ 2023-12-28T16:44:43+00:00 https://biolegacyresearch.com/jjs-acclarent-sees-fda-clearance-as-it-readies-for-acquisition-by-integra/ 2023-12-28T17:35:37+00:00 https://biolegacyresearch.com/whats-ahead-for-the-fda-in-2024/ 2023-12-29T16:15:36+00:00 https://biolegacyresearch.com/regulatory-update-week-of-dec-25-2023/ 2023-12-29T16:30:00+00:00 https://biolegacyresearch.com/biotelemetry-and-lifewatch-agree-to-pay-14-7-million-to-settle-false-claims-charges/ 2023-12-29T18:05:16+00:00 https://biolegacyresearch.com/draft-guidance-addresses-potency-assurance-for-human-cellular-and-gene-therapies/ 2023-12-29T18:35:03+00:00 https://biolegacyresearch.com/former-fda-chief-offers-three-avenues-for-regulating-disruptive-medical-technologies/ 2023-12-29T20:20:49+00:00 https://biolegacyresearch.com/fda-seeks-input-on-draft-report-plan-on-developing-new-guidances/ 2024-01-02T18:45:15+00:00 https://biolegacyresearch.com/document-cybersecurity-as-part-of-design-controls-expert-urges/ 2024-01-02T19:00:41+00:00 https://biolegacyresearch.com/fda-posts-three-form-483s-for-foreign-manufacturers/ 2024-01-02T19:15:19+00:00 https://biolegacyresearch.com/quick-notes-jan-2-2024/ 2024-01-02T20:00:33+00:00 https://biolegacyresearch.com/cdrh-switches-from-paper-to-electronic-for-export-documents/ 2024-01-03T18:38:00+00:00 https://biolegacyresearch.com/ftc-wins-temporary-injunction-halting-iqvia-propel-merger/ 2024-01-03T19:30:25+00:00 https://biolegacyresearch.com/court-finds-corcept-therapeutics-patents-not-infringed-by-teva/ 2024-01-03T20:00:37+00:00 https://biolegacyresearch.com/quick-notes-jan-3-2024/ 2024-01-03T21:00:44+00:00 https://biolegacyresearch.com/physician-congressman-writes-to-califf-urging-advancement-of-ai-rules/ 2024-01-04T19:40:10+00:00 https://biolegacyresearch.com/synovos-modified-total-hip-system-not-cleared-not-to-be-used-fda-says/ 2024-01-04T20:40:02+00:00 https://biolegacyresearch.com/lilly-launches-direct-to-consumer-program-for-diabetes-migraine-weight-loss-drugs/ 2024-01-04T21:30:28+00:00 https://biolegacyresearch.com/novo-nordisk-inks-two-new-research-collaborations-each-worth-up-to-532m/ 2024-01-04T22:10:34+00:00 https://biolegacyresearch.com/fda-authorizes-floridas-plan-to-import-drugs-from-canada/ 2024-01-05T17:30:29+00:00 https://biolegacyresearch.com/iqvia-propel-abandon-merger-after-ftc-wins-temporary-injunction/ 2024-01-05T17:50:51+00:00 https://biolegacyresearch.com/regulatory-update-week-of-jan-1-2024/ 2024-01-05T18:10:23+00:00 https://biolegacyresearch.com/house-committee-opens-inquiry-into-scientific-disagreements-at-the-fda/ 2024-01-05T19:55:13+00:00 https://biolegacyresearch.com/nature-study-says-weight-loss-blockbusters-dont-correlate-with-suicidal-ideation-just-days-after-fda-indicates-its-concern-over-the-risk/ 2024-01-05T20:25:42+00:00 https://biolegacyresearch.com/fda-recognizes-vaporized-hydrogen-peroxide-for-sterilization-in-lieu-of-eto/ 2024-01-08T19:35:41+00:00 https://biolegacyresearch.com/biden-directs-hhs-to-use-defense-production-act-to-shore-up-drug-supply-chain/ 2024-01-08T19:55:42+00:00 https://biolegacyresearch.com/boehringer-ingelheim-partners-with-ribo-in-2b-deal-to-develop-liver-therapies/ 2024-01-08T20:10:02+00:00 https://biolegacyresearch.com/new-study-shows-most-orphan-drugs-maintain-only-one-indication/ 2024-01-08T21:05:18+00:00 https://biolegacyresearch.com/fda-launches-new-webpage-to-search-for-documents-on-pharmaceutical-quality/ 2024-01-09T20:56:57+00:00 https://biolegacyresearch.com/three-major-drug-and-device-companies-announce-billion-dollar-acquisitions/ 2024-01-09T20:58:59+00:00 https://biolegacyresearch.com/crafting-an-ai-policy-for-protecting-medical-device-intellectual-property/ 2024-01-09T21:08:19+00:00 https://biolegacyresearch.com/quick-notes-on-recalls-jan-9-2024/ 2024-01-09T21:09:33+00:00 https://biolegacyresearch.com/help-committee-wants-answers-on-why-asthma-inhalers-cost-10x-more-in-u-s/ 2024-01-09T21:10:29+00:00 https://biolegacyresearch.com/cder-reports-on-55-new-drug-and-five-new-biosimilar-approvals-in-2023/ 2024-01-10T20:50:00+00:00 https://biolegacyresearch.com/mimedx-disputes-fda-warning-letter-on-axiofill/ 2024-01-10T21:00:06+00:00 https://biolegacyresearch.com/bd-settles-alaris-infusion-pump-class-action-suit-for-85-million/ 2024-01-10T21:10:39+00:00 https://biolegacyresearch.com/fraudulent-zombie-trials-live-on-in-literature-impacting-future-research/ 2024-01-10T21:20:13+00:00 https://biolegacyresearch.com/fda-highlights-eto-transition-challenges-during-device-sterilization-town-hall/ 2024-01-11T18:45:49+00:00 https://biolegacyresearch.com/califf-signals-desire-for-adaptive-algorithms-capable-of-change-in-medical-devices/ 2024-01-11T19:15:34+00:00 https://biolegacyresearch.com/two-guidances-focus-on-anda-reconsideration-and-viral-safety-of-biotech-products/ 2024-01-11T19:30:38+00:00 https://biolegacyresearch.com/fda-allows-importation-of-penicillin-from-france-to-address-syphilis-drug-shortage/ 2024-01-11T19:55:49+00:00 https://biolegacyresearch.com/uk-regulatory-agency-announces-roadmap-for-new-medical-technology-regulations/ 2024-01-12T20:30:46+00:00 https://biolegacyresearch.com/regulatory-update-week-of-jan-8-2024/ 2024-01-12T20:40:04+00:00 https://biolegacyresearch.com/fda-sees-no-evidence-of-suicidal-ideation-in-diabetes-diet-drugs/ 2024-01-12T20:50:28+00:00 https://biolegacyresearch.com/fda-labels-recalls-of-resmed-masks-busse-sterile-trays-fresenius-infusion-pumps/ 2024-01-12T21:00:41+00:00 https://biolegacyresearch.com/quick-notes-device-approvals-jan-12-2024/ 2024-01-12T21:10:50+00:00 https://biolegacyresearch.com/guest-column-florida-drug-import-program-will-take-time-affect-few-drugs/ 2024-01-16T20:30:03+00:00 https://biolegacyresearch.com/survey-reveals-physicians-have-limited-understanding-of-fda-drug-device-approvals/ 2024-01-16T20:40:42+00:00 https://biolegacyresearch.com/jama-study-analyzes-history-and-risks-of-ai-in-healthcare/ 2024-01-16T20:45:49+00:00 https://biolegacyresearch.com/legislation-to-streamline-drug-patent-litigation-introduced-in-house-and-senate/ 2024-01-16T20:50:49+00:00 https://biolegacyresearch.com/second-attempt-at-first-dna-based-oud-risk-test-wins-fda-approval/ 2024-01-16T20:55:54+00:00 https://biolegacyresearch.com/gene-edited-exa-cel-gets-second-approval-for-transfusion-dependent-beta-thalassemia/ 2024-01-17T20:15:06+00:00 https://biolegacyresearch.com/cder-office-of-compliance-2023-report-highlights-warning-letters-recalls/ 2024-01-17T20:30:54+00:00 https://biolegacyresearch.com/untrained-inexperienced-personnel-earn-california-drug-manufacturer-a-form-483/ 2024-01-17T21:15:46+00:00 https://biolegacyresearch.com/ema-cautions-mens-use-of-valproate-may-increase-risk-of-neuro-disorders-in-offspring/ 2024-01-17T21:25:00+00:00 https://biolegacyresearch.com/federal-judge-denies-coalition-protection-from-anti-kickback-laws/ 2024-01-18T19:55:22+00:00 https://biolegacyresearch.com/ema-marketing-recommendations-decline-to-77-in-2023/ 2024-01-18T20:10:44+00:00 https://biolegacyresearch.com/critical-medicines-alliance-to-recommend-policy-solutions-for-eu-drug-shortages/ 2024-01-18T21:10:01+00:00 https://biolegacyresearch.com/tillis-criticizes-bidens-intention-to-use-march-in-rights-to-control-drug-prices/ 2024-01-18T21:45:00+00:00 https://biolegacyresearch.com/regulatory-update-week-of-jan-15-2024/ 2024-01-19T18:07:28+00:00 https://biolegacyresearch.com/gao-accepts-senators-invite-to-investigate-fda-on-device-recalls/ 2024-01-19T20:16:20+00:00 https://biolegacyresearch.com/klobuchar-sanders-seek-answers-on-drug-prices-with-letters-subpoenas/ 2024-01-19T20:19:33+00:00 https://biolegacyresearch.com/newly-reorganized-fda-inspection-platform-expected-to-be-transformative/ 2024-01-19T23:02:01+00:00 https://biolegacyresearch.com/cms-fda-facing-critics-announce-mutual-support-for-fda-oversight-of-lab-tests/ 2024-01-19T23:15:59+00:00 https://biolegacyresearch.com/novartis-tv-ad-for-kisqali-overstates-effectiveness-fda-says-in-untitled-letter/ 2024-01-22T19:30:34+00:00 https://biolegacyresearch.com/cdrh-set-record-for-authorizing-novel-devices-in-2023-says-annual-report/ 2024-01-22T19:50:49+00:00 https://biolegacyresearch.com/legislative-update-week-of-jan-22-2024/ 2024-01-22T20:00:26+00:00 https://biolegacyresearch.com/amgens-osteoporosis-drug-prolia-gets-boxed-warning-for-potential-for-low-calcium/ 2024-01-22T20:10:28+00:00 https://biolegacyresearch.com/quick-notes-jan-22-2024/ 2024-01-22T20:20:19+00:00 https://biolegacyresearch.com/fda-issues-draft-guidance-on-premarket-submission-requirements-for-ortho-device-coatings/ 2024-01-23T19:25:00+00:00 https://biolegacyresearch.com/sanofi-to-acquire-inhibrx-in-2-billion-deal/ 2024-01-23T19:40:43+00:00 https://biolegacyresearch.com/ema-revised-drugmaker-user-guide-for-small-medium-companies-released/ 2024-01-23T19:50:33+00:00 https://biolegacyresearch.com/secondary-cancers-after-car-t-therapies-result-in-fda-boxed-warning/ 2024-01-23T21:05:31+00:00 https://biolegacyresearch.com/european-commission-seeks-another-delay-in-ivdr-compliance/ 2024-01-24T20:50:07+00:00 https://biolegacyresearch.com/novo-nordisk-partners-on-yet-another-weight-loss-drug/ 2024-01-24T20:55:35+00:00 https://biolegacyresearch.com/fda-final-guidance-advises-on-anda-labeling-updates-for-reference-drug-changes/ 2024-01-24T21:00:09+00:00 https://biolegacyresearch.com/canada-phrma-buck-fdas-approval-of-florida-plan-to-import-drugs-from-canada/ 2024-01-24T21:15:41+00:00 https://biolegacyresearch.com/illinois-drug-price-control-law-is-unconstitutional-generic-biosimilar-association-says/ 2024-01-25T20:10:06+00:00 https://biolegacyresearch.com/doj-drugmaker-attorneys-general-send-briefs-to-supreme-court-on-abortion-drug/ 2024-01-25T20:15:22+00:00 https://biolegacyresearch.com/doj-hhs-put-state-medicaid-offices-on-notice-about-hepatitis-c-medications/ 2024-01-25T20:20:31+00:00 https://biolegacyresearch.com/boxed-warning-designed-to-prompt-reporting-of-car-t-adverse-events-fda-says/ 2024-01-25T20:25:32+00:00 https://biolegacyresearch.com/update-on-fdas-ongoing-evaluation-of-reports-of-suicidal-thoughts-or-actions-in-patients-taking-a-certain-type-of-medicines-approved-for-type-2-diabetes-and-obesity/ 2024-01-26T14:32:03+00:00 https://biolegacyresearch.com/fda-kicks-off-qmm-assessment-tool-prototype-accepts-first-ai-l-into-istart-pilot/ 2024-01-26T20:00:58+00:00 https://biolegacyresearch.com/regulatory-update-week-of-jan-22-2024/ 2024-01-26T20:15:16+00:00 https://biolegacyresearch.com/apotex-two-other-generics-makers-settle-for-combined-45m-in-price-fixing-case/ 2024-01-26T20:30:50+00:00 https://biolegacyresearch.com/fda-clarifies-remote-regulatory-assessments-in-revised-qa-guidance/ 2024-01-26T20:35:55+00:00 https://biolegacyresearch.com/final-guidance-advises-on-amendments-to-tentatively-approved-andas/ 2024-01-26T20:40:00+00:00 https://biolegacyresearch.com/u-s-helium-supply-sale-catches-industry-off-guard-prompts-fears-of-shortage/ 2024-01-29T20:50:38+00:00 https://biolegacyresearch.com/fda-creates-tiger-team-to-address-efforts-to-reduce-use-of-eto-in-sterilization/ 2024-01-29T21:00:07+00:00 https://biolegacyresearch.com/gene-therapies-require-strong-preclinical-testing-new-guidances-say/ 2024-01-29T21:10:34+00:00 https://biolegacyresearch.com/quick-notes-european-edition-jan-29-2024/ 2024-01-29T21:20:49+00:00 https://biolegacyresearch.com/legislative-update-week-of-jan-29-2024/ 2024-01-29T21:30:41+00:00 https://biolegacyresearch.com/fda-expands-in-person-face-to-face-meetings-for-pdufa-bsufa-omufa/ 2024-01-30T18:45:32+00:00 https://biolegacyresearch.com/fda-elevates-office-of-strategic-partnerships-and-technology-innovation-to-super-office/ 2024-01-30T21:00:10+00:00 https://biolegacyresearch.com/fda-must-respond-to-vanda-request-for-answers-on-drug-denial-court-rules/ 2024-01-30T21:10:21+00:00 https://biolegacyresearch.com/fda-offers-final-draft-of-best-practices-for-postmarketing-safety-surveillance/ 2024-01-30T21:20:00+00:00 https://biolegacyresearch.com/35-briefs-supporting-fda-submitted-to-u-s-supreme-court-on-mifepristone-decision/ 2024-01-31T17:45:57+00:00 https://biolegacyresearch.com/advamed-asks-congress-to-pass-tax-provision-that-delays-5-year-rd-deduction/ 2024-01-31T17:55:47+00:00 https://biolegacyresearch.com/controversial-alzheimers-drug-aduhelm-now-pulled-made-history/ 2024-01-31T20:05:07+00:00 https://biolegacyresearch.com/fdas-long-awaited-qmsr-final-rule-harmonizes-u-s-and-intl-device-requirements/ 2024-01-31T21:13:00+00:00 https://biolegacyresearch.com/califf-says-fda-needs-much-more-staff-to-best-integrate-predictive-and-generative-ai/ 2024-02-01T20:05:50+00:00 https://biolegacyresearch.com/over-116000-mdrs-received-by-fda-for-philips-respirators-bipaps-cpaps/ 2024-02-01T20:15:19+00:00 https://biolegacyresearch.com/fda-issues-2024-priorities-for-cder-guidances-bsufa-research-roadmap/ 2024-02-01T20:25:14+00:00 https://biolegacyresearch.com/quick-notes-483-edition-feb-1-2024/ 2024-02-01T21:30:31+00:00 https://biolegacyresearch.com/research-roundup-february-2024/ 2024-02-02T20:50:45+00:00 https://biolegacyresearch.com/cdrh-to-reclassify-most-class-iii-ivds-as-class-ii-easing-approval-pathway/ 2024-02-02T20:55:21+00:00 https://biolegacyresearch.com/regulatory-update-week-of-jan-29-2024/ 2024-02-02T21:00:17+00:00 https://biolegacyresearch.com/fifth-circuits-mifepristone-decision-would-engender-regulatory-chaos-former-fda-officials-argue/ 2024-02-02T21:05:21+00:00 https://biolegacyresearch.com/despite-legal-challenges-medicare-moves-forward-on-drug-negotiations/ 2024-02-02T21:10:18+00:00 https://biolegacyresearch.com/novo-nordisk-to-acquire-three-catalent-fill-finish-sites-in-11b-deal/ 2024-02-05T21:10:55+00:00 https://biolegacyresearch.com/legislative-update-week-of-feb-5-2024/ 2024-02-05T21:20:17+00:00 https://biolegacyresearch.com/fda-panel-prefers-larger-clinical-trial-group-enhanced-labeling-for-pulse-oximeters/ 2024-02-05T22:10:01+00:00 https://biolegacyresearch.com/340b-bipartisan-senate-proposal-targets-duplicate-discounts-adds-user-fees/ 2024-02-05T22:15:03+00:00 https://biolegacyresearch.com/fifth-circuits-mifepristone-decision-undercuts-judicial-review-says-bar-association/ 2024-02-05T22:20:18+00:00 https://biolegacyresearch.com/fda-adds-boxed-warning-for-increased-risk-of-severe-hypocalcemia-in-patients-with-advanced-chronic-kidney-disease-taking-osteoporosis-medicine-prolia-denosumab/ 2024-02-06T18:22:36+00:00 https://biolegacyresearch.com/troubled-philips-gets-yet-another-recall-considered-class-i-by-fda/ 2024-02-06T19:15:26+00:00 https://biolegacyresearch.com/drug-reporting-requirements-to-take-effect-feb-26-following-final-guidance/ 2024-02-06T19:30:40+00:00 https://biolegacyresearch.com/researchers-analyze-glp-1-patent-thickets-for-proper-listing-of-drug-device-combo/ 2024-02-06T20:20:18+00:00 https://biolegacyresearch.com/fda-is-a-no-show-at-congressional-hearing-on-inspections-of-foreign-drug-plants/ 2024-02-06T22:00:24+00:00 https://biolegacyresearch.com/percussionaire-recalls-high-frequency-transport-phasitron-breathing-circuit-kits/ 2024-02-07T17:30:59+00:00 https://biolegacyresearch.com/fda-panel-debates-what-mission-critical-devices-506j-list-should-include/ 2024-02-07T18:55:39+00:00 https://biolegacyresearch.com/ftc-supports-march-in-rights-to-control-prices-and-stimulate-competition/ 2024-02-07T19:15:44+00:00 https://biolegacyresearch.com/fdas-ocp-conducted-5600-ind-reviews-in-2023-says-annual-report/ 2024-02-07T20:00:12+00:00 https://biolegacyresearch.com/vanda-suit-claims-fda-disregards-statutory-deadlines-for-application-decisions/ 2024-02-08T17:50:59+00:00 https://biolegacyresearch.com/ema-proposes-relaxed-requirements-for-biosimilars/ 2024-02-08T17:54:40+00:00 https://biolegacyresearch.com/quick-notes-device-approvals-feb-8-2024/ 2024-02-08T18:43:52+00:00 https://biolegacyresearch.com/notification-process-for-drug-shortages-explained-in-draft-guidance/ 2024-02-08T18:47:12+00:00 https://biolegacyresearch.com/pharma-ceos-blame-high-drug-prices-on-pbms-in-senate-help-committee-hearing/ 2024-02-09T17:35:08+00:00 https://biolegacyresearch.com/misinformation-threatens-public-health-fda-official-says/ 2024-02-09T20:50:34+00:00 https://biolegacyresearch.com/hhs-recognizes-need-to-evaluate-pricing-not-just-availability-for-march-in-rights/ 2024-02-09T20:55:09+00:00 https://biolegacyresearch.com/regulatory-update-week-of-feb-5-2024/ 2024-02-09T21:00:41+00:00 https://biolegacyresearch.com/consumers-right-to-repair-rules-could-damage-patient-safety-advamed-says/ 2024-02-09T21:25:41+00:00 https://biolegacyresearch.com/semaglutide-compounders-forced-to-stop-sales-advertise-dangers-of-unapproved-drugs/ 2024-02-12T20:00:51+00:00 https://biolegacyresearch.com/report-names-misuse-of-home-medical-devices-the-top-health-tech-safety-hazard/ 2024-02-12T20:10:41+00:00 https://biolegacyresearch.com/final-rule-codifies-long-standing-practice-for-blas-to-reference-drug-master-file-data/ 2024-02-12T20:20:43+00:00 https://biolegacyresearch.com/legislative-update-week-of-feb-12-2024/ 2024-02-12T20:30:25+00:00 https://biolegacyresearch.com/masimo-pulse-oximetry-accurate-for-varying-skin-tones-low-perfusion-study-finds/ 2024-02-12T21:45:11+00:00 https://biolegacyresearch.com/guest-column-fda-tackling-promotional-messages-in-letters-regulations/ 2024-02-13T18:00:44+00:00 https://biolegacyresearch.com/inspection-of-api-manufacturer-in-china-shows-nonexistent-qc-documentation/ 2024-02-13T18:15:53+00:00 https://biolegacyresearch.com/amt-guidance-would-hinder-cell-and-gene-therapy-progress-commentators-charge/ 2024-02-13T18:30:35+00:00 https://biolegacyresearch.com/texas-judge-dismisses-phrma-led-suit-against-ira-on-jurisdictional-technicality/ 2024-02-13T20:35:14+00:00 https://biolegacyresearch.com/fda-cracking-down-on-fake-diabetes-weight-loss-drugs-in-warning-letters/ 2024-02-14T21:35:58+00:00 https://biolegacyresearch.com/ftc-and-hhs-seek-info-on-how-industry-middlemen-affect-generic-industry/ 2024-02-14T21:45:25+00:00 https://biolegacyresearch.com/abbotts-triclip-gets-adcomm-thumbs-up-for-tricuspid-regurgitation/ 2024-02-14T21:55:24+00:00 https://biolegacyresearch.com/fda-draft-guidance-modernizes-use-of-data-monitoring-committees/ 2024-02-14T22:05:26+00:00 https://biolegacyresearch.com/early-version-software-issues-cause-class-i-recall-for-medfusion-4000-syringe-pump/ 2024-02-15T17:45:08+00:00 https://biolegacyresearch.com/califf-calls-for-greater-accuracy-balance-in-health-care-reporting/ 2024-02-15T21:25:41+00:00 https://biolegacyresearch.com/quick-notes-device-news-feb-15-2024/ 2024-02-15T21:35:14+00:00 https://biolegacyresearch.com/fda-finalizes-guidance-on-charging-for-investigational-drugs-takes-other-actions/ 2024-02-15T21:45:18+00:00 https://biolegacyresearch.com/dayton-chambers-suit-against-the-ira-lacks-standing-should-be-dismissed-hhs-says/ 2024-02-16T19:35:57+00:00 https://biolegacyresearch.com/regulatory-update-week-of-feb-12-2024/ 2024-02-16T19:45:15+00:00 https://biolegacyresearch.com/senators-urge-fda-to-crack-down-on-misleading-social-media-prescription-drug-ads/ 2024-02-16T20:05:09+00:00 https://biolegacyresearch.com/two-pharma-behemoths-reach-contrasting-settlement-agreements/ 2024-02-16T20:35:39+00:00 https://biolegacyresearch.com/combatting-substance-abuse-highlights-cders-2023-accomplishments/ 2024-02-16T21:00:40+00:00 https://biolegacyresearch.com/new-ruling-revives-lawsuit-against-sanofi-for-low-dosing-fabry-disease-drug/ 2024-02-20T20:15:19+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-feb-20-2024/ 2024-02-20T20:25:28+00:00 https://biolegacyresearch.com/real-world-data-catalogues-expected-to-upgrade-medicines-regulation-in-europe/ 2024-02-20T20:35:19+00:00 https://biolegacyresearch.com/fda-should-be-more-active-in-regulating-devices-say-academicians/ 2024-02-21T21:15:09+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-feb-21-2024/ 2024-02-21T21:20:38+00:00 https://biolegacyresearch.com/chinese-firm-must-comply-with-remediation-or-face-import-ban-warning-letter-says/ 2024-02-21T21:25:54+00:00 https://biolegacyresearch.com/draft-guidance-explains-fda-fee-reduction-for-troubled-small-devicemakers/ 2024-02-21T21:30:43+00:00 https://biolegacyresearch.com/fda-warns-of-smartwatches-smart-rings-that-claim-to-measure-blood-glucose-levels/ 2024-02-22T21:25:15+00:00 https://biolegacyresearch.com/medical-device-industry-ai-principles-published-by-advamed/ 2024-02-22T21:55:01+00:00 https://biolegacyresearch.com/eu-tightens-regulations-on-medical-devices-to-prevent-shortages/ 2024-02-22T22:05:50+00:00 https://biolegacyresearch.com/five-companies-refuse-to-delist-ftc-challenged-orange-book-patents-three-others-comply/ 2024-02-22T22:45:34+00:00 https://biolegacyresearch.com/regulatory-update-week-of-feb-19-2024/ 2024-02-23T17:00:39+00:00 https://biolegacyresearch.com/fda-updates-advice-on-evaluating-common-symptoms-in-outpatient-covid-19-trials/ 2024-02-23T18:15:22+00:00 https://biolegacyresearch.com/quick-notes-medical-device-news-feb-23-2024/ 2024-02-23T18:25:03+00:00 https://biolegacyresearch.com/industry-says-it-needs-more-time-to-comply-with-drug-supply-chain-security-requirements/ 2024-02-23T22:00:50+00:00 https://biolegacyresearch.com/fda-office-of-generic-drugs-annual-report-touts-successful-2023/ 2024-02-23T22:10:06+00:00 https://biolegacyresearch.com/fda-pulls-multiple-myeloma-drug-pepaxto-from-market-after-failing-phase-3-study/ 2024-02-26T21:05:55+00:00 https://biolegacyresearch.com/fda-asking-for-more-data-on-ai-based-medical-device-submissions/ 2024-02-26T21:10:30+00:00 https://biolegacyresearch.com/a-win-a-loss-and-a-draw-for-more-fda-action-on-trial-reporting-noncompliance/ 2024-02-26T21:15:17+00:00 https://biolegacyresearch.com/manufacturing-issues-result-in-crl-for-venatorx-cuti-drug/ 2024-02-26T21:20:29+00:00 https://biolegacyresearch.com/legislative-update-week-of-feb-26-2024/ 2024-02-26T21:25:28+00:00 https://biolegacyresearch.com/emas-chmp-recommends-10-medicines-six-indication-extensions-of-approval/ 2024-02-27T18:50:00+00:00 https://biolegacyresearch.com/stakeholders-request-clarity-on-particulates-in-ophthalmic-drugs-quality-guidance/ 2024-02-27T20:45:35+00:00 https://biolegacyresearch.com/final-guidance-details-how-to-submit-drug-volume-reports/ 2024-02-27T21:10:48+00:00 https://biolegacyresearch.com/quick-notes-drug-news-feb-27-2024/ 2024-02-27T21:55:27+00:00 https://biolegacyresearch.com/fda-warns-of-serious-risks-with-hologic-biozorb-marker-implants/ 2024-02-28T20:15:04+00:00 https://biolegacyresearch.com/volume-of-counterfeit-drugs-coming-into-u-s-is-huge-says-fda-commissioner/ 2024-02-28T20:30:42+00:00 https://biolegacyresearch.com/crl-for-minervas-schizophrenia-drug-cites-multiple-clinical-and-nonclinical-issues/ 2024-02-28T20:45:26+00:00 https://biolegacyresearch.com/pressure-mounts-to-reform-pbms-but-companies-are-heel-dragging-on-ftcs-investigation/ 2024-02-28T21:05:04+00:00 https://biolegacyresearch.com/contaminated-eye-drops-spur-fda-to-issue-three-warning-letters/ 2024-02-29T20:55:41+00:00 https://biolegacyresearch.com/rwe-draft-guidance-could-be-burdensome-to-device-manufacturers-commentors-note/ 2024-02-29T21:10:12+00:00 https://biolegacyresearch.com/medtronic-faces-two-issues-class-i-recall-and-patent-infringement-lawsuit/ 2024-02-29T21:20:14+00:00 https://biolegacyresearch.com/teva-argues-feds-should-be-held-to-higher-standard-on-patient-assistance-cases/ 2024-02-29T21:50:51+00:00 https://biolegacyresearch.com/endo-health-solutions-agrees-to-plead-guilty-pay-2-billion-to-resolve-fines-bankruptcy/ 2024-03-01T19:40:32+00:00 https://biolegacyresearch.com/regulatory-update-week-of-feb-26-2024/ 2024-03-01T19:55:52+00:00 https://biolegacyresearch.com/quick-notes-device-safety-and-recalls-march-1-2024/ 2024-03-01T20:10:10+00:00 https://biolegacyresearch.com/manufacturers-want-more-federal-guidance-sooner-on-integrating-ai-survey-finds/ 2024-03-01T20:55:09+00:00 https://biolegacyresearch.com/fda-modernizes-informed-consent-guidance-aligning-with-common-rule-changes/ 2024-03-01T21:05:14+00:00 https://biolegacyresearch.com/adcomm-to-review-risks-of-cancer-detecting-combo-for-breast-lumpectomy/ 2024-03-04T20:20:23+00:00 https://biolegacyresearch.com/legislative-update-week-of-march-4-2024/ 2024-03-04T20:30:40+00:00 https://biolegacyresearch.com/datex-ohmeda-recalls-air-compressors-due-to-formaldehyde-emissions/ 2024-03-04T20:35:54+00:00 https://biolegacyresearch.com/quick-notes-device-clearances-march-4-2024/ 2024-03-04T20:40:31+00:00 https://biolegacyresearch.com/astrazeneca-loses-ira-challenge-in-federal-court-decision/ 2024-03-04T21:10:56+00:00 https://biolegacyresearch.com/biden-touts-participation-on-all-10-drugs-in-ira-price-negotiation-program/ 2024-03-05T20:00:16+00:00 https://biolegacyresearch.com/vanda-gets-its-answer-from-the-fda-on-its-request-for-a-hearing-on-hetlioz/ 2024-03-05T20:30:35+00:00 https://biolegacyresearch.com/ge-healthcare-ai-models-use-available-clinical-data-in-predicting-accurate-outcomes/ 2024-03-05T21:40:48+00:00 https://biolegacyresearch.com/digital-health-tools-could-improve-diabetes-diagnosis-and-management/ 2024-03-05T21:50:03+00:00 https://biolegacyresearch.com/fda-adcomm-gives-thumbs-up-to-drug-device-combo-in-breast-cancer-lumpectomy/ 2024-03-06T20:00:40+00:00 https://biolegacyresearch.com/first-otc-continuous-glucose-monitor-cleared-by-the-fda/ 2024-03-06T20:04:45+00:00 https://biolegacyresearch.com/fresenius-kabi-warned-of-penalties-for-noncompliance-in-fda-letter/ 2024-03-06T20:55:30+00:00 https://biolegacyresearch.com/biden-strike-force-launches-public-inquiry-into-healthcare-practices/ 2024-03-06T21:25:02+00:00 https://biolegacyresearch.com/senators-join-fight-against-biden-plan-to-use-march-in-rights-to-lower-drug-costs/ 2024-03-07T18:55:28+00:00 https://biolegacyresearch.com/fda-endorses-pair-of-ich-final-guidelines-on-analytical-procedures/ 2024-03-07T19:05:28+00:00 https://biolegacyresearch.com/optimal-use-of-ai-in-healthcare-will-require-solid-infrastructure-califf-says/ 2024-03-07T19:20:50+00:00 https://biolegacyresearch.com/software-error-causes-recall-of-baxter-exactamix-for-over-delivery-of-ingredients/ 2024-03-07T19:35:07+00:00 https://biolegacyresearch.com/regulatory-update-week-of-march-4-2024/ 2024-03-08T17:29:42+00:00 https://biolegacyresearch.com/medtronic-recall-of-drainage-and-monitoring-system-catheter-tubing-deemed-class-1/ 2024-03-08T17:32:57+00:00 https://biolegacyresearch.com/ec-fleshes-out-how-regulators-and-developers-will-implement-health-technology-assessments/ 2024-03-08T17:35:16+00:00 https://biolegacyresearch.com/declining-approval-for-lillys-donanemab-fda-refers-the-antiamyloid-to-adcomm-scrutiny/ 2024-03-08T18:54:23+00:00 https://biolegacyresearch.com/in-sotu-address-biden-says-medicare-will-negotiate-prices-of-500-drugs-in-10-years/ 2024-03-08T18:57:40+00:00 https://biolegacyresearch.com/president-biden-signs-the-fda-budget-for-fiscal-year-2024/ 2024-03-09T19:03:43+00:00 https://biolegacyresearch.com/improved-communication-is-key-to-bringing-new-products-to-market-fda-director-says/ 2024-03-11T18:00:28+00:00 https://biolegacyresearch.com/medtronic-catheter-tubing-ventec-breathing-package-see-class-i-recalls/ 2024-03-11T18:23:00+00:00 https://biolegacyresearch.com/legislative-update-week-of-march-11-2024/ 2024-03-11T18:27:00+00:00 https://biolegacyresearch.com/pa-drug-manufacturer-charged-3-5m-in-penalties-resulting-from-cgmp-violations/ 2024-03-11T20:03:57+00:00 https://biolegacyresearch.com/draft-guidance-says-asymptomatic-people-should-be-included-in-alzheimers-trials/ 2024-03-11T21:00:21+00:00 https://biolegacyresearch.com/consumer-dermatology-apps-inconsistent-not-fda-approved-says-jama-study/ 2024-03-12T17:49:29+00:00 https://biolegacyresearch.com/unexpected-pump-starts-and-stops-bring-class-1-recall-for-abbott-heart-device/ 2024-03-12T17:55:42+00:00 https://biolegacyresearch.com/draft-guidances-address-device-cybersecurity-nonprescription-drug-labeling-changes/ 2024-03-12T17:58:52+00:00 https://biolegacyresearch.com/fda-requests-7-2b-in-funding-for-fy25-an-increase-of-495m/ 2024-03-12T18:53:22+00:00 https://biolegacyresearch.com/quick-notes-drug-news-march-13-2024/ 2024-03-13T18:55:02+00:00 https://biolegacyresearch.com/fda-draft-guidance-updates-definitions-and-standards-for-postapproval-safety-data/ 2024-03-13T19:05:52+00:00 https://biolegacyresearch.com/advanced-manufacturing-guidance-needs-detail-on-benefits-comments-say/ 2024-03-13T21:25:05+00:00 https://biolegacyresearch.com/company-seeking-stool-for-fecal-transplants-earns-fda-warning-letter/ 2024-03-13T21:40:26+00:00 https://biolegacyresearch.com/two-medical-device-draft-guidances-detail-q-submission-process-thermal-effects/ 2024-03-14T17:35:34+00:00 https://biolegacyresearch.com/par-pharmaceutical-recalls-treprostinil-injection-due-to-silicone-particulates/ 2024-03-14T17:50:39+00:00 https://biolegacyresearch.com/research-roundup-march-2024/ 2024-03-14T18:20:17+00:00 https://biolegacyresearch.com/hatch-waxman-amendments-drug-shortages-lead-fdas-2025-legislative-agenda/ 2024-03-14T19:25:58+00:00 https://biolegacyresearch.com/epa-publishes-final-eto-amendments-aimed-at-reducing-emissions-by-90-percent/ 2024-03-15T16:55:51+00:00 https://biolegacyresearch.com/first-treatment-for-nash-gets-fda-approval/ 2024-03-15T17:15:35+00:00 https://biolegacyresearch.com/regulatory-update-week-of-march-11-2024/ 2024-03-15T17:30:48+00:00 https://biolegacyresearch.com/fda-panel-endorses-gerons-anemia-drug-for-group-of-blood-cancers/ 2024-03-15T18:10:38+00:00 https://biolegacyresearch.com/fda-finalizes-controlled-correspondence-guidance-for-generic-drugmakers/ 2024-03-15T18:20:11+00:00 https://biolegacyresearch.com/adcomm-supports-using-two-approved-car-t-cancer-treatments-earlier-in-multiple-myeloma/ 2024-03-18T18:25:59+00:00 https://biolegacyresearch.com/fda-outlines-areas-of-focus-for-the-development-and-regulation-of-ai-technologies/ 2024-03-18T18:35:23+00:00 https://biolegacyresearch.com/indian-chemotherapy-drug-manufacturer-dinged-with-483/ 2024-03-18T18:45:33+00:00 https://biolegacyresearch.com/legislative-update-week-of-march-18-2024/ 2024-03-18T18:55:41+00:00 https://biolegacyresearch.com/medical-devices-need-top-priority-in-supply-chain-conference-speakers-say/ 2024-03-18T19:05:52+00:00 https://biolegacyresearch.com/first-gene-therapy-for-children-with-metachromatic-leukodystrophy-approved-by-fda/ 2024-03-19T18:30:29+00:00 https://biolegacyresearch.com/guidance-focuses-on-impact-of-impaired-renal-function-in-studies-dosage-labeling/ 2024-03-19T18:40:08+00:00 https://biolegacyresearch.com/quick-notes-device-news-march-19-2024/ 2024-03-19T20:35:12+00:00 https://biolegacyresearch.com/two-deals-beef-up-astrazenecas-cancer-rare-disease-groups/ 2024-03-19T20:45:32+00:00 https://biolegacyresearch.com/how-fda-interlaced-iso-13485-into-the-quality-management-system-regulation/ 2024-03-20T18:00:08+00:00 https://biolegacyresearch.com/fda-proposed-rule-addresses-demonstrably-difficult-compounded-drugs-categories/ 2024-03-20T18:10:31+00:00 https://biolegacyresearch.com/plastic-syringe-makers-under-fire-from-fda-as-agency-updates-warning-sends-letters/ 2024-03-20T18:25:31+00:00 https://biolegacyresearch.com/proposed-eu-drug-legislation-shortens-data-protection-by-6-months-for-new-products/ 2024-03-20T18:35:56+00:00 https://biolegacyresearch.com/federal-coverage-of-weight-loss-drugs-could-bloat-national-debt-cbo-says/ 2024-03-21T20:15:44+00:00 https://biolegacyresearch.com/quick-notes-device-news-march-21-2024/ 2024-03-21T20:25:05+00:00 https://biolegacyresearch.com/fda-gives-direction-on-using-rwd-in-noninterventional-studies/ 2024-03-21T20:35:54+00:00 https://biolegacyresearch.com/valid-act-is-better-than-fdas-proposed-ldt-rule-hearing-speakers-say/ 2024-03-21T20:50:33+00:00 https://biolegacyresearch.com/syringe-maker-confident-it-can-resolve-issues-in-fda-warning-letter/ 2024-03-22T18:55:18+00:00 https://biolegacyresearch.com/quick-notes-european-edition-march-22-2024/ 2024-03-22T19:10:35+00:00 https://biolegacyresearch.com/regulatory-update-week-of-march-18-2024/ 2024-03-22T19:20:36+00:00 https://biolegacyresearch.com/three-recalls-a-heart-pump-associated-with-49-deaths-a-resuscitator-and-an-infusion-system/ 2024-03-22T19:30:37+00:00 https://biolegacyresearch.com/fda-panel-gives-thumbs-up-to-balance-ophthalmics-ocular-pressure-pump/ 2024-03-22T19:40:04+00:00 https://biolegacyresearch.com/ftc-finds-another-way-to-force-teva-to-delist-patents-from-orange-book/ 2024-03-25T18:20:15+00:00 https://biolegacyresearch.com/expanding-embracing-sterilization-standards-endorsed-in-fda-webinar/ 2024-03-25T18:30:11+00:00 https://biolegacyresearch.com/quick-notes-drug-news-march-25-2024/ 2024-03-25T18:58:21+00:00 https://biolegacyresearch.com/new-ban-of-electrical-stimulation-devices-proposed-rule-issued-by-fda/ 2024-03-25T20:35:53+00:00 https://biolegacyresearch.com/new-quantitative-medicine-center-of-excellence-established-by-cder/ 2024-03-26T18:45:36+00:00 https://biolegacyresearch.com/second-consultation-opens-for-ema-draft-guidance-on-advanced-therapy-products/ 2024-03-26T19:05:39+00:00 https://biolegacyresearch.com/retention-of-bioresearch-investigators-a-major-issue-for-fda-gao-report-says/ 2024-03-26T20:40:55+00:00 https://biolegacyresearch.com/fda-guidance-outlines-procedures-for-ba-be-testing-samples-handling-retention/ 2024-03-26T20:50:21+00:00 https://biolegacyresearch.com/high-levels-of-lidocaine-in-otc-numbing-products-prompts-six-fda-warning-letters/ 2024-03-27T20:15:25+00:00 https://biolegacyresearch.com/ec-seeks-comments-on-benefit-risk-of-phthalates-in-medical-devices/ 2024-03-27T20:30:38+00:00 https://biolegacyresearch.com/cell-gene-therapies-unique-attributes-set-them-apart-say-comments-on-draft-guidance/ 2024-03-27T20:55:18+00:00 https://biolegacyresearch.com/astrazeneca-files-suit-to-block-arkansas-expansion-of-340b-program/ 2024-03-27T21:10:15+00:00 https://biolegacyresearch.com/another-move-to-improve-supply-chain-traceability-comes-as-customs-teams-with-fda/ 2024-03-28T17:20:26+00:00 https://biolegacyresearch.com/otc-monograph-facility-fee-rates-increase-by-23-percent/ 2024-03-28T18:20:46+00:00 https://biolegacyresearch.com/sen-sanders-rips-novo-nordisk-calls-for-drastically-reduced-ozempic-pricing/ 2024-03-28T19:40:38+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-device-clearance-march-28-2024/ 2024-03-28T20:25:32+00:00 https://biolegacyresearch.com/fda-drafts-guidance-on-animal-studies-for-dental-bone-grafting-material-devices/ 2024-03-29T18:45:59+00:00 https://biolegacyresearch.com/regulatory-update-week-of-march-25-2024/ 2024-03-29T19:00:13+00:00 https://biolegacyresearch.com/drug-prices-set-under-ira-could-be-less-than-actual-value-researchers-say/ 2024-03-29T19:35:51+00:00 https://biolegacyresearch.com/first-molecular-test-to-screen-blood-donors-for-malaria-approved-by-fda/ 2024-03-29T20:00:07+00:00 https://biolegacyresearch.com/following-pilot-program-asca-takes-root-to-streamline-medical-device-review/ 2024-03-29T20:20:24+00:00 https://biolegacyresearch.com/fda-publishes-list-of-drugs-with-cgt-designation-to-encourage-generic-competition/ 2024-04-01T18:50:05+00:00 https://biolegacyresearch.com/electronic-submission-of-safety-reports-is-subject-of-three-fda-final-guidances/ 2024-04-01T19:00:51+00:00 https://biolegacyresearch.com/legislative-update-week-of-april-1-2024/ 2024-04-01T19:05:21+00:00 https://biolegacyresearch.com/policy-papers-outline-cders-role-in-assessing-rems-plans/ 2024-04-01T19:10:15+00:00 https://biolegacyresearch.com/smartphone-testing-for-dementia-shows-promising-results/ 2024-04-01T19:20:31+00:00 https://biolegacyresearch.com/draft-guidance-doesnt-fully-address-new-high-tech-coatings-commenter-says/ 2024-04-02T19:50:07+00:00 https://biolegacyresearch.com/draft-guidance-stresses-corporate-commitment-to-quality-for-ba-be-drug-study-data/ 2024-04-02T20:00:53+00:00 https://biolegacyresearch.com/guest-column-medical-innovation-needed-to-analyze-drug-cost-effectiveness/ 2024-04-02T20:20:27+00:00 https://biolegacyresearch.com/quick-notes-drug-news-april-2-2024/ 2024-04-02T20:30:54+00:00 https://biolegacyresearch.com/draft-guidance-comments-rras-beneficial-but-need-more-explanation/ 2024-04-03T19:50:13+00:00 https://biolegacyresearch.com/quick-notes-device-news-april-3-2024/ 2024-04-03T20:00:57+00:00 https://biolegacyresearch.com/483s-plague-astrazeneca-and-lilly/ 2024-04-03T20:10:34+00:00 https://biolegacyresearch.com/biden-iras-drug-cost-cutting-should-be-made-available-to-all-americans/ 2024-04-03T20:20:29+00:00 https://biolegacyresearch.com/ars-pharma-sends-crl-response-to-fda-for-its-nasal-spray-replacement-for-epipen/ 2024-04-04T19:40:26+00:00 https://biolegacyresearch.com/three-medical-device-recalls-identified-as-class-i-by-fda/ 2024-04-04T19:55:30+00:00 https://biolegacyresearch.com/ai-sepsis-diagnostic-tool-gets-fda-nod/ 2024-04-04T20:05:03+00:00 https://biolegacyresearch.com/after-reviewing-negative-topline-data-amylyx-pulls-als-drug-from-market/ 2024-04-04T20:15:58+00:00 https://biolegacyresearch.com/one-multi-billion-dollar-acquisition-held-up-on-ftc-review-another-announced/ 2024-04-05T16:40:45+00:00 https://biolegacyresearch.com/regulatory-update-week-of-april-1-2024/ 2024-04-05T17:00:04+00:00 https://biolegacyresearch.com/policy-fixes-needed-for-record-high-drug-shortages-say-researchers/ 2024-04-05T19:05:31+00:00 https://biolegacyresearch.com/opq-report-details-2023-office-achievements-in-four-strategic-priorities/ 2024-04-05T20:05:41+00:00 https://biolegacyresearch.com/physicians-researchers-urge-fda-to-revoke-approval-of-genetic-tests-for-oud/ 2024-04-05T20:10:43+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-april-8-2024/ 2024-04-08T18:25:17+00:00 https://biolegacyresearch.com/legislative-update-week-of-april-8-2024/ 2024-04-08T18:55:49+00:00 https://biolegacyresearch.com/two-combination-products-see-fda-issue-crls/ 2024-04-08T19:28:47+00:00 https://biolegacyresearch.com/most-accelerated-approval-cancer-meds-dont-live-up-to-their-promise-says-study/ 2024-04-08T19:35:10+00:00 https://biolegacyresearch.com/hhs-white-paper-cites-accomplishments-and-goals-in-tackling-drug-shortages/ 2024-04-08T19:50:09+00:00 https://biolegacyresearch.com/pharma-quality-expert-touts-benefits-of-ich-q10/ 2024-04-09T18:40:25+00:00 https://biolegacyresearch.com/cder-annual-report-highlights-communication-efforts-to-strengthen-public-trust/ 2024-04-09T18:50:59+00:00 https://biolegacyresearch.com/quick-notes-device-clearances-and-approvals-april-9-2024/ 2024-04-09T19:55:37+00:00 https://biolegacyresearch.com/support-wanes-on-fda-proposal-regulating-ldts-as-medical-devices/ 2024-04-09T20:45:39+00:00 https://biolegacyresearch.com/barefoot-employees-fabricated-test-results-earn-eye-drop-manufacturer-an-fda-warning-letter/ 2024-04-10T18:25:40+00:00 https://biolegacyresearch.com/philips-cpap-bipap-ventilators-restricted-from-production-under-consent-decree/ 2024-04-10T18:35:02+00:00 https://biolegacyresearch.com/pbms-suppressing-humira-biosimilars-sales-causing-low-market-share-report-finds/ 2024-04-10T19:50:57+00:00 https://biolegacyresearch.com/fda-rethinking-automatic-30-month-stay-in-patent-thickets-after-endo-sues/ 2024-04-10T20:55:57+00:00 https://biolegacyresearch.com/doj-files-against-regeneron-for-inflated-drug-price-reporting/ 2024-04-11T19:00:12+00:00 https://biolegacyresearch.com/cleaning-and-maintenance-failures-cited-in-cipla-form-483/ 2024-04-11T19:10:14+00:00 https://biolegacyresearch.com/strong-biosimilar-performance-increases-market-share-decreases-prices-report-says/ 2024-04-11T19:20:17+00:00 https://biolegacyresearch.com/eu-parliament-adopts-position-on-pharma-reform-data-and-environmental-protection/ 2024-04-11T19:40:01+00:00 https://biolegacyresearch.com/drug-shortages-reached-all-time-high-last-year-says-report/ 2024-04-12T17:25:48+00:00 https://biolegacyresearch.com/fda-needs-access-to-more-info-from-drugmakers-to-address-shortages-califf-tells-congress/ 2024-04-12T17:35:16+00:00 https://biolegacyresearch.com/regulatory-update-week-of-april-8-2024/ 2024-04-12T18:45:18+00:00 https://biolegacyresearch.com/avoid-chinese-plastic-syringes-fda-recommends-to-providers-and-consumers/ 2024-04-12T19:50:15+00:00 https://biolegacyresearch.com/in-dismissing-suit-judge-says-lilly-cant-use-state-law-to-enforce-the-fdc-act/ 2024-04-12T20:20:48+00:00 https://biolegacyresearch.com/form-483-slaps-zydus-with-four-observations/ 2024-04-15T19:35:05+00:00 https://biolegacyresearch.com/cder-to-award-700000-for-gathering-input-on-medical-product-policy-development/ 2024-04-15T19:45:49+00:00 https://biolegacyresearch.com/legislative-update-week-of-april-15-2024/ 2024-04-15T19:55:30+00:00 https://biolegacyresearch.com/new-cder-center-seeks-innovative-clinical-trial-designs-for-demo-project/ 2024-04-15T20:05:52+00:00 https://biolegacyresearch.com/fda-needs-114m-to-fund-federal-government-pay-increases-says-agency-cfo/ 2024-04-15T20:25:46+00:00 https://biolegacyresearch.com/14-deaths-involving-abbott-thoratec-heartmate-lvas-result-in-class-i-recall/ 2024-04-16T19:20:16+00:00 https://biolegacyresearch.com/eugia-pharma-sees-three-483s-since-january-following-inspections-of-plants-in-india/ 2024-04-16T19:35:17+00:00 https://biolegacyresearch.com/cdrh-unveils-dataset-of-chemicals-to-test-biocompatibility-of-medical-devices/ 2024-04-16T19:45:45+00:00 https://biolegacyresearch.com/pbms-dont-want-states-regulating-them-gao-report-finds/ 2024-04-16T20:10:22+00:00 https://biolegacyresearch.com/claims-that-cardiac-device-grows-new-arteries-earn-devicemaker-fda-warning-letter/ 2024-04-17T19:00:34+00:00 https://biolegacyresearch.com/fake-botox-harms-19-prompting-federal-investigations/ 2024-04-17T19:10:55+00:00 https://biolegacyresearch.com/ema-touts-its-new-real-world-evidence-capabilities-to-researchers/ 2024-04-17T19:30:51+00:00 https://biolegacyresearch.com/increasing-cancer-trial-access-in-india-is-goal-of-new-fda-collaboration/ 2024-04-17T19:32:00+00:00 https://biolegacyresearch.com/fresenius-kabis-ivenix-infusion-system-suffers-another-class-i-recall/ 2024-04-18T18:47:45+00:00 https://biolegacyresearch.com/cdrh-2024-reports-highlight-steps-to-keep-up-with-new-technology-ensure-safety/ 2024-04-18T18:55:55+00:00 https://biolegacyresearch.com/api-could-be-national-security-issue-but-thats-a-market-problem-califf/ 2024-04-18T19:05:59+00:00 https://biolegacyresearch.com/quick-notes-medical-device-clearances-april-18-2024/ 2024-04-18T19:10:00+00:00 https://biolegacyresearch.com/regulatory-update-week-of-april-15-2024/ 2024-04-19T15:55:00+00:00 https://biolegacyresearch.com/ema-launches-medicine-shortages-monitoring-platform/ 2024-04-19T18:05:32+00:00 https://biolegacyresearch.com/use-regulatory-intelligence-for-supplier-management-quality-expert-says/ 2024-04-19T18:20:45+00:00 https://biolegacyresearch.com/form-483-with-oai-issued-to-sun-pharmas-dadra-facility/ 2024-04-19T18:25:30+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-april-19-2024/ 2024-04-19T20:20:01+00:00 https://biolegacyresearch.com/new-portal-enables-public-to-report-anticompetitive-healthcare-practices/ 2024-04-22T16:30:19+00:00 https://biolegacyresearch.com/legislative-update-week-of-april-22-2024/ 2024-04-22T16:40:20+00:00 https://biolegacyresearch.com/research-roundup-april-2024/ 2024-04-22T17:00:25+00:00 https://biolegacyresearch.com/cder-confirms-prescription-med-info-will-be-one-page/ 2024-04-22T18:20:35+00:00 https://biolegacyresearch.com/judge-upholds-kickback-suit-for-allergans-promotion-of-botox-for-pediatric-migraine/ 2024-04-22T18:30:22+00:00 https://biolegacyresearch.com/takeda-and-astellas-partner-with-banking-giant-on-early-drug-discovery/ 2024-04-23T16:50:59+00:00 https://biolegacyresearch.com/exactech-finally-conducts-recall-of-equinoxe-shoulder-implants/ 2024-04-23T18:35:56+00:00 https://biolegacyresearch.com/ema-unveils-recommendations-to-tackle-critical-medicine-shortages/ 2024-04-23T19:15:07+00:00 https://biolegacyresearch.com/most-biomarkers-supporting-drug-approvals-lack-strong-supporting-data-study-says/ 2024-04-23T19:22:30+00:00 https://biolegacyresearch.com/fda-kicks-off-next-gen-home-healthcare-device-development-program/ 2024-04-24T17:25:35+00:00 https://biolegacyresearch.com/cbers-marks-pushes-for-accelerated-approval-in-gene-therapies-for-rare-diseases/ 2024-04-24T17:35:25+00:00 https://biolegacyresearch.com/fda-advice-on-labeling-advertising-biologics-updated-in-revised-draft-guidance/ 2024-04-24T17:45:20+00:00 https://biolegacyresearch.com/most-postmarketing-reports-on-schedule-in-2022-report-finds/ 2024-04-24T20:15:04+00:00 https://biolegacyresearch.com/warning-letter-cites-philips-for-ct-manufacturing-site-in-china/ 2024-04-25T17:20:36+00:00 https://biolegacyresearch.com/fda-ocp-seeks-public-input-on-drug-development-clinical-pharmacology-programs/ 2024-04-25T17:45:14+00:00 https://biolegacyresearch.com/sanders-senate-help-committee-investigating-novo-nordisk-price-gouging-in-us/ 2024-04-25T19:15:20+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-april-25-2024/ 2024-04-25T19:40:38+00:00 https://biolegacyresearch.com/draft-guidance-assists-in-writing-nda-anda-drug-component-list-to-speed-approval/ 2024-04-26T18:15:45+00:00 https://biolegacyresearch.com/regulatory-update-week-of-april-22-2024/ 2024-04-26T18:25:04+00:00 https://biolegacyresearch.com/marketing-of-problem-laden-syringes-earns-cardinal-health-fda-warning-letter/ 2024-04-26T18:35:01+00:00 https://biolegacyresearch.com/european-parliament-greenlights-second-deadline-extension-for-ivd-makers/ 2024-04-26T19:10:18+00:00 https://biolegacyresearch.com/quick-notes-four-class-i-device-recalls-april-26-2024/ 2024-04-26T19:35:44+00:00 https://biolegacyresearch.com/brain-biopsy-needle-that-could-leave-behind-steel-debris-sees-class-i-recall/ 2024-04-29T17:00:42+00:00 https://biolegacyresearch.com/legislative-update-week-of-april-29-2024/ 2024-04-29T17:15:25+00:00 https://biolegacyresearch.com/more-than-10-percent-of-globally-manufactured-apis-linked-to-us-drug-shortages/ 2024-04-29T18:50:36+00:00 https://biolegacyresearch.com/ftcs-finalized-hbnr-adds-teeth-to-health-apps-tech-not-covered-by-hipaa/ 2024-04-29T19:25:06+00:00 https://biolegacyresearch.com/final-rule-declares-ivds-to-be-devices-regulated-by-the-fda/ 2024-04-29T19:55:06+00:00 https://biolegacyresearch.com/final-rule-declares-ldts-to-be-devices-regulated-by-the-fda/ 2024-04-29T19:55:06+00:00 https://biolegacyresearch.com/jjs-bristol-myers-challenges-to-medicare-drug-price-negotiations-squashed/ 2024-04-30T19:10:50+00:00 https://biolegacyresearch.com/fda-seeks-public-input-on-advisory-committee-processes/ 2024-04-30T19:25:18+00:00 https://biolegacyresearch.com/quick-notes-draft-guidances-april-30-2024/ 2024-04-30T19:35:56+00:00 https://biolegacyresearch.com/form-483-slams-zydus-for-drug-contamination-employee-untruthfulness-and-more/ 2024-04-30T19:50:41+00:00 https://biolegacyresearch.com/ftc-targets-300-junk-patents-with-warning-letters-including-ozempic/ 2024-05-01T18:30:42+00:00 https://biolegacyresearch.com/fda-continues-crackdown-on-semaglutide-imposters/ 2024-05-01T18:38:50+00:00 https://biolegacyresearch.com/fda-sets-two-class-i-recalls-for-sonarmed-airway-monitors-one-for-biomerieux-test-kits/ 2024-05-01T18:45:06+00:00 https://biolegacyresearch.com/most-oncology-approvals-using-surrogate-endpoints-lack-postmarket-confirmation-study-says/ 2024-05-01T18:50:00+00:00 https://biolegacyresearch.com/ts-research-addresses-fda-warning-letter-satisfactorily/ 2024-05-01T21:30:58+00:00 https://biolegacyresearch.com/wp-content/uploads/2023/05/btsresearchLogo.png https://biolegacyresearch.com/apple-watch-afib-history-feature-qualified-for-use-in-medical-device-development/ 2024-05-02T17:00:35+00:00 https://biolegacyresearch.com/head-of-fdas-ora-worried-budget-woes-could-lead-to-fewer-inspections/ 2024-05-02T17:15:43+00:00 https://biolegacyresearch.com/quick-notes-device-clearances-and-approvals-may-2-2024/ 2024-05-02T19:15:38+00:00 https://biolegacyresearch.com/skinny-labeled-generics-saved-medicare-billions-over-six-years/ 2024-05-02T20:25:32+00:00 https://biolegacyresearch.com/icer-researcher-raises-concern-over-possible-fda-full-approval-of-dmd-treatment/ 2024-05-03T18:30:00+00:00 https://biolegacyresearch.com/regulatory-update-week-of-april-29-2024/ 2024-05-03T18:40:37+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-may-3-2024/ 2024-05-03T20:38:41+00:00 https://biolegacyresearch.com/cders-offices-of-new-drugs-transitional-services-unveil-2023-annual-reports/ 2024-05-03T20:48:29+00:00 https://biolegacyresearch.com/ema-reflection-paper-tackles-real-world-data-in-non-interventional-studies/ 2024-05-03T20:52:42+00:00 https://biolegacyresearch.com/legislative-update-week-of-may-6-2024/ 2024-05-06T18:30:18+00:00 https://biolegacyresearch.com/evaluation-of-rems-outcomes-to-be-baked-into-applications-says-guidance/ 2024-05-06T18:40:50+00:00 https://biolegacyresearch.com/multiple-quality-observations-in-form-483-earn-maryland-company-warning-letter-as-well/ 2024-05-06T18:50:30+00:00 https://biolegacyresearch.com/quick-notes-device-clearances-may-6-2024/ 2024-05-06T19:10:09+00:00 https://biolegacyresearch.com/gao-report-critical-of-hhs-emergency-stockpile-management-offers-recommendations/ 2024-05-06T19:20:36+00:00 https://biolegacyresearch.com/ema-joins-four-other-eu-agencies-in-one-health-task-force/ 2024-05-07T18:00:55+00:00 https://biolegacyresearch.com/fdas-adcomms-returning-to-in-person-soon-says-cavazzoni/ 2024-05-07T18:15:01+00:00 https://biolegacyresearch.com/uk-regulator-unveils-plans-for-ai-as-a-medical-device/ 2024-05-07T19:10:47+00:00 https://biolegacyresearch.com/most-with-high-risk-alzheimers-gene-develop-biologically-defined-ad/ 2024-05-07T20:00:54+00:00 https://biolegacyresearch.com/missing-heparin-coating-on-tubing-earns-bioptimal-fda-warning-letter/ 2024-05-08T17:05:11+00:00 https://biolegacyresearch.com/advisory-committee-will-dig-into-alzheimers-drug-donanemab-next-month/ 2024-05-08T18:00:55+00:00 https://biolegacyresearch.com/cahill-senate-budget-testimony-features-largest-reorg-in-fda-history/ 2024-05-08T20:30:52+00:00 https://biolegacyresearch.com/fda-nih-seek-input-on-clinical-trial-innovation-glossary/ 2024-05-08T20:40:59+00:00 https://biolegacyresearch.com/final-guidance-clarifies-remanufacturing-of-medical-devices/ 2024-05-09T17:45:24+00:00 https://biolegacyresearch.com/software-glitch-results-in-class-i-recall-of-mobile-app-for-insulin-pump/ 2024-05-09T18:05:48+00:00 https://biolegacyresearch.com/safety-quality-concerns-cause-fda-to-issue-alert-on-getinge-maquet-cardiac-devices/ 2024-05-09T19:25:15+00:00 https://biolegacyresearch.com/regulatory-plan-calls-on-fda-usda-and-epa-to-coordinate-on-biotechnology-products/ 2024-05-09T20:05:41+00:00 https://biolegacyresearch.com/health-care-monopoly-and-collusion-task-force-formed-by-doj/ 2024-05-10T19:00:53+00:00 https://biolegacyresearch.com/regulatory-update-week-of-may-6-2024/ 2024-05-10T19:10:35+00:00 https://biolegacyresearch.com/medical-device-reporting-violations-merit-company-an-fda-warning-letter/ 2024-05-10T19:20:32+00:00 https://biolegacyresearch.com/uk-regulator-tackles-aiamd-with-ai-airlock-launch/ 2024-05-10T19:30:13+00:00 https://biolegacyresearch.com/quick-notes-device-clearances-and-approvals-may-10-2024/ 2024-05-10T19:40:40+00:00 https://biolegacyresearch.com/legislative-update-week-of-may-13-2024/ 2024-05-13T16:35:12+00:00 https://biolegacyresearch.com/megadyne-discontinues-recalls-pediatric-patient-return-electrodes/ 2024-05-13T16:50:38+00:00 https://biolegacyresearch.com/contractor-gets-route-92-medical-catheters-class-i-recall-due-to-distal-tip-separation/ 2024-05-13T18:35:01+00:00 https://biolegacyresearch.com/contamination-insufficient-training-highlight-latest-form-483-for-allied-medical/ 2024-05-13T20:40:17+00:00 https://biolegacyresearch.com/updated-biosecure-act-gives-companies-up-to-eight-years-to-wrap-up-contracts/ 2024-05-13T21:12:25+00:00 https://biolegacyresearch.com/troubled-philips-again-recalls-trilogy-evo-ventilators-for-power-malfunction/ 2024-05-14T17:45:40+00:00 https://biolegacyresearch.com/cue-health-must-cease-sale-marketing-of-covid-19-tests-following-inspection/ 2024-05-14T18:00:46+00:00 https://biolegacyresearch.com/philips-sues-cpap-cleaning-system-soclean-to-contribute-to-1-1-billion-settlement/ 2024-05-14T19:15:24+00:00 https://biolegacyresearch.com/accused-of-pre-authorization-promotion-sandoz-dumps-uk-prescription-medicines-code-of-practice-authority/ 2024-05-14T19:30:20+00:00 https://biolegacyresearch.com/team-nb-annual-survey-shows-increases-in-applications-certificates-issued/ 2024-05-15T18:05:41+00:00 https://biolegacyresearch.com/supply-chain-disruption-planning-will-cease-without-funding-cdrhs-shuren-says/ 2024-05-15T18:30:21+00:00 https://biolegacyresearch.com/conservative-think-tank-challenges-notion-of-excessive-profits-for-drugmakers/ 2024-05-15T19:20:13+00:00 https://biolegacyresearch.com/destruction-of-data-by-clinical-trial-site-results-in-crl-for-dynavax-hepatitis-b-drug/ 2024-05-15T19:40:49+00:00 https://biolegacyresearch.com/post-approval-patent-thickets-protect-americas-priciest-drugs-study-says/ 2024-05-16T18:45:32+00:00 https://biolegacyresearch.com/abbott-heartmate-sees-third-class-i-recall-this-year/ 2024-05-16T19:15:50+00:00 https://biolegacyresearch.com/eli-lilly-victorious-in-case-against-med-spa-for-selling-fake-diabetes-weight-loss-drugs/ 2024-05-16T19:25:56+00:00 https://biolegacyresearch.com/32-new-and-revised-product-specific-draft-guidances-published-by-fda/ 2024-05-16T19:35:26+00:00 https://biolegacyresearch.com/legislative-update-week-of-may-20-2024/ 2024-05-20T18:45:47+00:00 https://biolegacyresearch.com/two-more-chinese-manufacturers-syringes-blocked-from-entering-us/ 2024-05-20T19:00:45+00:00 https://biolegacyresearch.com/guest-column-direct-to-consumer-medical-marketing-enters-new-era/ 2024-05-20T19:15:30+00:00 https://biolegacyresearch.com/eugias-form-483-file-keeps-growing/ 2024-05-20T19:30:42+00:00 https://biolegacyresearch.com/race-act-has-boosted-pediatric-oncology-drug-studies-fda-says/ 2024-05-20T19:35:54+00:00 https://biolegacyresearch.com/women-rural-residents-conservatives-least-likely-to-trust-fda-survey-says/ 2024-05-21T17:50:56+00:00 https://biolegacyresearch.com/quick-notes-ma-and-collaborations-may-21-2024/ 2024-05-21T18:00:05+00:00 https://biolegacyresearch.com/without-incentive-funding-antibiotic-development-will-plummet-association-says/ 2024-05-21T18:15:20+00:00 https://biolegacyresearch.com/patent-thickets-wont-be-stopped-until-fda-and-uspto-collaborate-better-say-senators-and-experts/ 2024-05-21T19:00:53+00:00 https://biolegacyresearch.com/biologic-manufacturer-fails-to-test-for-diseases-gets-fda-warning-letter/ 2024-05-22T17:50:30+00:00 https://biolegacyresearch.com/magellan-diagnostics-agrees-to-plead-guilty-pay-42-million/ 2024-05-22T20:15:57+00:00 https://biolegacyresearch.com/nih-proposes-patent-agreements-with-partners-who-receive-their-funding/ 2024-05-22T20:30:07+00:00 https://biolegacyresearch.com/where-companies-go-wrong-in-responses-to-fda-form-483-inspection-observations/ 2024-05-22T21:15:37+00:00 https://biolegacyresearch.com/lawmakers-question-chide-fda-leaders-at-congressional-hearing/ 2024-05-23T17:50:11+00:00 https://biolegacyresearch.com/adcomm-must-balance-benefit-of-once-weekly-insulin-with-risk-of-severe-hypoglycemia/ 2024-05-23T17:53:10+00:00 https://biolegacyresearch.com/bms-sanofi-owe-916m-after-hawaii-retrial-over-plavix/ 2024-05-23T19:58:34+00:00 https://biolegacyresearch.com/dc-circuit-upholds-ruling-allowing-drugmakers-to-restrict-deliveries-to-contract-pharmacies/ 2024-05-23T20:26:15+00:00 https://biolegacyresearch.com/regulatory-update-week-of-may-20-2024/ 2024-05-24T15:18:32+00:00 https://biolegacyresearch.com/cder-science-research-efforts-that-support-generics-detailed-in-2023-annual-report/ 2024-05-24T15:49:40+00:00 https://biolegacyresearch.com/biozorb-markers-and-twin-tubes-get-recalls-designated-class-i/ 2024-05-24T16:21:51+00:00 https://biolegacyresearch.com/dem-senators-urge-fdas-califf-to-reclaim-regulation-of-lethal-injection-drugs/ 2024-05-24T18:42:33+00:00 https://biolegacyresearch.com/colorectal-cancer-blood-test-gets-adcomm-ok-as-primary-screening-tool/ 2024-05-24T18:46:59+00:00 https://biolegacyresearch.com/lilly-to-boost-api-production-for-tirzepatide-and-pipeline-medicines/ 2024-05-28T15:52:23+00:00 https://biolegacyresearch.com/fda-draft-guidance-seeks-comments-on-drug-platform-tech-designation/ 2024-05-28T15:54:22+00:00 https://biolegacyresearch.com/louisiana-law-classifies-mifepristone-and-misoprostol-as-controlled-substances/ 2024-05-28T17:51:57+00:00 https://biolegacyresearch.com/hypoglycemia-risk-trips-once-weekly-insulin-at-adcomm/ 2024-05-28T18:02:25+00:00 https://biolegacyresearch.com/quick-notes-device-clearances-may-29-2024/ 2024-05-29T17:20:14+00:00 https://biolegacyresearch.com/ich-issues-final-guidance-on-drug-interactions-draft-guidance-on-drug-safety-studies/ 2024-05-29T17:50:51+00:00 https://biolegacyresearch.com/amgens-bkemv-earns-fda-approval-as-first-interchangeable-biosimilar-to-soliris/ 2024-05-29T18:10:04+00:00 https://biolegacyresearch.com/data-breach-puts-patient-info-at-privacy-risk-for-a-dozen-pharmaceutical-makers/ 2024-05-29T18:25:18+00:00 https://biolegacyresearch.com/eu-gmp-report-may-2024/ 2024-05-30T17:20:01+00:00 https://biolegacyresearch.com/yet-another-recall-for-philips-ventilators-with-reports-of-10-injuries-7-deaths/ 2024-05-30T17:35:46+00:00 https://biolegacyresearch.com/innovasis-to-pay-12-million-to-settle-anti-kickback-allegations/ 2024-05-30T18:25:51+00:00 https://biolegacyresearch.com/first-lawsuit-filed-attempting-to-block-fdas-final-rule-on-ldts/ 2024-05-30T18:35:47+00:00 https://biolegacyresearch.com/fda-final-rule-allows-for-destruction-of-illegal-devices-refused-admission-to-us/ 2024-05-31T17:20:10+00:00 https://biolegacyresearch.com/regulatory-update-week-of-may-27-2024/ 2024-05-31T17:45:23+00:00 https://biolegacyresearch.com/research-report-may-2024/ 2024-05-31T18:00:06+00:00 https://biolegacyresearch.com/eu-likes-dupixent-for-copd-but-fda-needs-more-time-to-decide/ 2024-05-31T19:58:13+00:00 https://biolegacyresearch.com/novo-nordisk-sues-over-copycat-semaglutide-points-to-serious-adverse-reactions/ 2024-05-31T20:05:27+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-june-3-2024/ 2024-06-03T18:30:33+00:00 https://biolegacyresearch.com/multiple-potential-failure-points-leads-to-optumhealth-infusion-pump-class-i-recall/ 2024-06-03T18:40:27+00:00 https://biolegacyresearch.com/legislative-update-week-of-june-3-2024/ 2024-06-03T18:50:15+00:00 https://biolegacyresearch.com/mdma-makes-patients-feel-so-good-that-trials-might-be-compromised-fda-worries/ 2024-06-03T19:00:40+00:00 https://biolegacyresearch.com/generic-drug-manufacturers-want-ftc-to-investigate-gpo-drug-wholesaler-practices/ 2024-06-03T19:10:40+00:00 https://biolegacyresearch.com/delaware-superior-court-gives-go-ahead-on-more-than-70000-zantac-trials/ 2024-06-04T18:50:09+00:00 https://biolegacyresearch.com/novartis-phrma-suits-seek-to-stop-wv-and-md-340b-expansions/ 2024-06-04T19:00:07+00:00 https://biolegacyresearch.com/planning-for-bioresearch-monitoring-inspections-is-subject-of-two-draft-guidances/ 2024-06-04T20:25:27+00:00 https://biolegacyresearch.com/chinese-car-t-cell-research-developer-cited-with-15-observations-on-form-483/ 2024-06-04T20:35:43+00:00 https://biolegacyresearch.com/congressional-hearing-on-340b-program-calls-for-more-transparency/ 2024-06-05T19:25:51+00:00 https://biolegacyresearch.com/mdma-ptsd-treatment-soundly-rejected-by-fda-advisory-committee/ 2024-06-05T19:35:52+00:00 https://biolegacyresearch.com/two-canadian-devicemakers-get-fda-warning-letters-for-cgmp-marketing-issues/ 2024-06-05T19:45:50+00:00 https://biolegacyresearch.com/streamline-biosimilar-development-to-reduce-costs-increase-patient-access-aam-says/ 2024-06-05T19:52:08+00:00 https://biolegacyresearch.com/us-pharmacopeia-and-fda-report-on-numbers-of-and-reasons-for-drug-shortages/ 2024-06-06T16:30:30+00:00 https://biolegacyresearch.com/embattled-vanda-drug-gets-fda-notice-of-refusal-to-approve/ 2024-06-06T18:55:52+00:00 https://biolegacyresearch.com/hands-free-diabetes-management-made-possible-with-dexcom-g7-cgm/ 2024-06-06T19:00:18+00:00 https://biolegacyresearch.com/corrosion-black-mold-bad-toilets-and-trashed-documents-highlight-form-483/ 2024-06-06T19:05:09+00:00 https://biolegacyresearch.com/biomea-fusion-diabetes-drug-clinical-trials-placed-on-fda-hold/ 2024-06-07T16:55:12+00:00 https://biolegacyresearch.com/regulatory-update-week-of-june-3-2024/ 2024-06-07T18:10:04+00:00 https://biolegacyresearch.com/adcomm-will-tussle-with-donanemabs-high-aria-rate-in-june-10-meeting/ 2024-06-07T18:35:44+00:00 https://biolegacyresearch.com/megadyne-and-medtronic-both-see-class-i-recalls/ 2024-06-07T18:50:32+00:00 https://biolegacyresearch.com/gao-report-on-otc-hearing-aids-confirms-barriers-remain-costs-remain-high/ 2024-06-07T19:35:39+00:00 https://biolegacyresearch.com/quick-notes-medical-device-news-june-10-2024/ 2024-06-10T17:45:53+00:00 https://biolegacyresearch.com/legislative-update-week-of-june-10-2024/ 2024-06-10T17:55:20+00:00 https://biolegacyresearch.com/cder-announces-pharmacovigilance-emerging-technologies-meetings/ 2024-06-10T18:05:21+00:00 https://biolegacyresearch.com/inspection-expert-offers-tips-for-responding-to-fdas-document-requests/ 2024-06-10T18:15:31+00:00 https://biolegacyresearch.com/fda-chooses-seven-rare-disease-therapies-for-start/ 2024-06-10T19:00:24+00:00 https://biolegacyresearch.com/human-umbilical-cord-product-lacks-ind-bla-company-slapped-with-untitled-letter/ 2024-06-11T16:50:36+00:00 https://biolegacyresearch.com/adcomm-unanimously-supports-lillys-antiamyloid-antibody-for-alzheimers/ 2024-06-11T17:00:30+00:00 https://biolegacyresearch.com/teva-must-remove-proair-hfa-device-patents-from-orange-book-judge-orders/ 2024-06-11T17:10:30+00:00 https://biolegacyresearch.com/advamed-wins-appeal-in-right-to-repair-over-library-of-congress/ 2024-06-11T18:35:16+00:00 https://biolegacyresearch.com/alzheimers-trials-guidance-feedback-calls-for-clarity-on-disease-later-stage-protocols/ 2024-06-12T16:45:23+00:00 https://biolegacyresearch.com/abbott-heartmate-sees-4th-class-i-recall-medline-sees-recall-for-endotracheal-tube/ 2024-06-12T17:00:59+00:00 https://biolegacyresearch.com/houses-proposed-budget-offers-fda-no-new-funding/ 2024-06-12T17:15:38+00:00 https://biolegacyresearch.com/fda-research-strives-to-understand-the-ever-evolving-world-of-ai-powered-devices/ 2024-06-12T17:45:42+00:00 https://biolegacyresearch.com/supreme-court-rejects-challenge-to-mifepristone/ 2024-06-13T19:25:53+00:00 https://biolegacyresearch.com/patients-in-europe-wait-an-average-531-days-to-get-new-medicines-says-report/ 2024-06-13T19:35:15+00:00 https://biolegacyresearch.com/fda-grants-two-year-dscsa-exemption-to-small-dispensers/ 2024-06-13T19:40:48+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-june-13-2024/ 2024-06-13T19:45:57+00:00 https://biolegacyresearch.com/regulatory-update-week-of-june-10-2024/ 2024-06-14T17:20:56+00:00 https://biolegacyresearch.com/class-i-recalls-for-getinge-anesthesia-vaporizers-arrow-cardiac-balloon-catheters/ 2024-06-14T17:35:58+00:00 https://biolegacyresearch.com/machine-learning-enabled-medical-device-transparency-principles-issued-by-fda/ 2024-06-14T17:50:12+00:00 https://biolegacyresearch.com/fda-gets-7-hours-of-feedback-on-adcomm-makeup-and-processes/ 2024-06-14T19:05:53+00:00 https://biolegacyresearch.com/fda-finalizes-guidances-for-oligonucleotides-drugs-for-diabetic-foot-infections/ 2024-06-14T19:15:19+00:00 https://biolegacyresearch.com/legislative-update-week-of-june-17-2024/ 2024-06-17T16:45:36+00:00 https://biolegacyresearch.com/fda-switches-strains-on-covid-19-vaccines-for-this-fall/ 2024-06-17T18:25:54+00:00 https://biolegacyresearch.com/483-dings-florida-compounder-for-recurring-problems/ 2024-06-17T18:35:17+00:00 https://biolegacyresearch.com/quick-notes-eu-edition-june-17-2024/ 2024-06-17T19:40:43+00:00 https://biolegacyresearch.com/fda-unveils-final-rule-on-new-regulations-for-medical-gases/ 2024-06-17T20:05:54+00:00 https://biolegacyresearch.com/fda-issues-final-guidance-on-facility-readiness-and-gdufa-goal-dates/ 2024-06-18T17:50:18+00:00 https://biolegacyresearch.com/fdas-proposed-rule-seeks-to-restrict-drug-compounding-group-claims/ 2024-06-18T18:30:02+00:00 https://biolegacyresearch.com/warning-letters-up-drug-recalls-down-in-fy-2023-cder-drug-quality-report/ 2024-06-18T18:52:39+00:00 https://biolegacyresearch.com/340b-program-spending-up-nearly-20-percent-a-year-from-2010-to-2021-says-cbo-report/ 2024-06-18T19:20:22+00:00 https://biolegacyresearch.com/fda-issues-guidance-on-biosimilar-interchangeability-with-reference-products/ 2024-06-20T17:13:59+00:00 https://biolegacyresearch.com/ftc-registers-support-for-uspto-proposal-on-patent-proceedings-highlighting-pharma/ 2024-06-20T18:20:18+00:00 https://biolegacyresearch.com/for-overweight-kids-behavior-modification-beats-weight-loss-drugs-task-force-says/ 2024-06-20T18:35:57+00:00 https://biolegacyresearch.com/draft-guidance-on-rwe-needs-more-detail-to-be-useful-says-industry/ 2024-06-20T18:55:11+00:00 https://biolegacyresearch.com/regulatory-update-week-of-june-17-2024/ 2024-06-21T17:00:23+00:00 https://biolegacyresearch.com/quick-notes-drug-approvals-june-21-2024/ 2024-06-21T18:00:30+00:00 https://biolegacyresearch.com/dr-reddys-new-483-joins-more-than-dozen-others-in-last-dozen-years/ 2024-06-21T18:15:21+00:00 https://biolegacyresearch.com/lilly-files-fake-tirzepatide-lawsuits-who-pharmacy-group-add-their-own-warnings/ 2024-06-21T18:30:37+00:00 https://biolegacyresearch.com/fda-unveils-final-guidance-for-justifying-drug-device-inspection-delays-denials/ 2024-06-21T19:00:11+00:00 https://biolegacyresearch.com/fda-updates-list-of-recognized-consensus-standards-for-medical-devices/ 2024-06-24T17:00:08+00:00 https://biolegacyresearch.com/legislative-update-week-of-june-24-2024/ 2024-06-24T17:15:48+00:00 https://biolegacyresearch.com/quick-notes-device-approvals-june-24-2024/ 2024-06-24T17:30:17+00:00 https://biolegacyresearch.com/fda-usp-work-to-promote-generics-development-for-off-patent-meds/ 2024-06-24T17:45:06+00:00 https://biolegacyresearch.com/with-ldts-as-medical-devices-rule-about-to-take-effect-fda-issues-guidance/ 2024-06-24T19:35:02+00:00 https://biolegacyresearch.com/novo-nordisk-to-invest-4-1b-in-us-plant-to-increase-ozempic-wegovy-production/ 2024-06-25T18:50:34+00:00 https://biolegacyresearch.com/comments-sought-for-fda-it-and-customer-service-strategies/ 2024-06-25T19:10:31+00:00 https://biolegacyresearch.com/house-republicans-press-califf-for-answers-on-foreign-inspection-irregularities/ 2024-06-25T19:30:51+00:00 https://biolegacyresearch.com/modernization-efforts-are-streamlining-regulatory-processes-fda-report-finds/ 2024-06-25T19:45:07+00:00